[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 72 of about 72
1. Li X, Yang C, Su Z, Song Y: [The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Sep;15(9):401-2, 404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer].
  • OBJECTIVE: The correlation of multidrug resistance(MDR) phenotype with clinical response to chemotherapy was investigated in patients with laryngeal cancer.
  • METHOD: Tumor specimens prior to neoadjuvant chemotherapy from 36 cases of laryngeal cancer were collected for detection of P-glycoprotein (P-gp) with anti-Pgp monoclonal antibodies (JSB-I).
  • Immunohistochemical assays were used for P-gp detection on 5 microns thick frozen section.
  • Anti-Pgp monoclonal antibodies(JSB-I) as primary antibodies and goat anti-mouse IgG monoclonal antibodies as second antibodies were applied.
  • All patients received preoperative induction chemotherapy with a regimen of cisplatin, 5-fluorouracil and pingyangmycin.
  • Evaluation for tumor response was scored as follows: Response to chemotherapy was graded as good for complete response or partial response; as poor for stable disease or progressive disease.
  • CONCLUSION: These preliminary data suggest that a significant correlation between MDR phenotype, Pgp-mediated and chemotherapy resistance existed.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Laryngeal Neoplasms / drug therapy. P-Glycoprotein / analysis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12541888.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


2. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We found a higher frequency of laryngeal tumour in group 2 (31 vs 17; p =.03).
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • Cancer was the first cause of death in both groups.
  • The overall survival of the population (108 patients) was 81.5% at one year, 49.6% at 3 years and 35.3% at 5 years with a median survival of 3 years.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • If confirmed, cost effectiveness of such complication must be integrated in larynx preservation protocols.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst; 2009 Apr 1;101(7):498-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
  • BACKGROUND: Chemotherapy with cisplatin (P) and 5-fluorouracil (F) followed by radiotherapy in patients who respond to chemotherapy is an alternative to total laryngectomy for patients with locally advanced larynx and hypopharynx cancer.
  • The objective of this trial was to determine whether adding T to PF could increase the larynx preservation rate.
  • METHODS: Patients who had larynx and hypopharynx cancer that required total laryngectomy were randomly assigned to receive three cycles of TPF or PF.
  • Patients who responded to chemotherapy received radiotherapy with or without additional chemotherapy.
  • Patients who did not respond to chemotherapy underwent total laryngectomy followed by radiotherapy with or without additional chemotherapy.
  • The primary endpoint was 3-year larynx preservation rate.
  • Secondary endpoints included acute toxicities and overall response.
  • RESULTS: Baseline patient and tumor characteristics were well balanced between the TPF (n = 110) and PF (n = 103) groups.
  • With a median follow-up of 36 months, the 3-year actuarial larynx preservation rate was 70.3% with TPF vs 57.5% with PF (difference = 12.8%; P = .03).
  • CONCLUSIONS: In patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.
  • These results suggest that larynx preservation could be achieved for a higher proportion of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Laryngectomy / methods. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Taxoids / administration & dosage. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Aug 19;101(16):1157-8; author reply 1158 [19567423.001]
  • (PMID = 19318632.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Védrine L, Chargari C, Le Moulec S, Fayolle M, Ceccaldi B, Bauduceau O: [Cancer chemotherapy of the upper aerodigestive tract]. Cancer Radiother; 2008 Mar;12(2):110-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer chemotherapy of the upper aerodigestive tract].
  • [Transliterated title] Chimiothérapie des cancers des voies aérodigestives supérieures.
  • Tumours of the upper aerodigestive tract represent the sixth most frequent kind of cancer in France and throughout the world.
  • If the localised forms may be controlled in the long run in two thirds of cases by surgery or radiotherapy, only one third of locally advanced forms are accessible to a cure after association from radiotherapy and chemotherapy.
  • Besides, with a median of survival less than six months, metastatic tumours present a catastrophic spontaneous prognosis among patients with a medical ground that is often heavily deteriorated by prolonged exposure to alcohol and tobacco.
  • Thus, there is a necessity to implement adapted therapeutic strategies to each patient and based on satisfactory proof levels of effectiveness.
  • Optimisation of existing chemotherapy protocols and development of new therapies, in particular of targeted therapies, remain an important objective in the hope to improve results of treatments in locally advanced and metastatic cancers of the oral cavity.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Combined Modality Therapy. Humans. Laryngeal Neoplasms / drug therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187355.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


5. Tanaka A, Ohsawa H, Ikeda H, Koshiba R: [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina]. Kyobu Geka; 2002 Jul;55(7):537-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
  • A 64-year-old male, who had received successful radiotherapy for the previous laryngeal cancer, was admitted to our department for the treatment of a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina.
  • The endotracheal biopsy of the carinal tumor demonstrated squamous cell carcinoma, though preoperative examination of the intrapulmonary tumor was unable to clarify it's pathological type.
  • The intrapulmonary tumor required right upper lobectomy and R2 lymph node dissection as a measure against the possibility of primary lung cancer.
  • Since the endotracheal cancer was diagnosed as an intra mucosal tumor by the preoperative computed tomography (CT) scans and the bronchoscopic examination, laser abrasion therapy to the endotracheal tumor was performed 4 days before the lobectomy of the intrapulmonary tumor.
  • After the pulmonary operation, the intrapulmonary tumor was diagnosed as squamous cell carcinoma without lymph node metastasis, and it was suggested to be a metastatic tumor of the previous laryngeal cancer.
  • Both radiotherapy to the carina and general chemotherapy with docetaxel hydrate and carboplatin were used as adjuvant therapies 36 days after the lobectomy.
  • One year after the pulmonary surgery, there is no recurrence of the tumor in the lung or carina.
  • Laser abrasion therapy to the endotracheal tumor is very useful and safe for the patient, who should then receive pulmonary resection soon after the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Paclitaxel / analogs & derivatives. Pneumonectomy. Taxoids. Tracheal Neoplasms / surgery
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Laser Therapy. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12136580.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • The main causes of death were metachronous second primary tumors (n = 27) and intercurrent disease (n = 21).
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • The 1-year and 5-year Kaplan-Meier local control estimates were 76.1% and 50.7%, respectively.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • CONCLUSIONS: For selected patients, EC may provide long-term, durable disease control.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


7. Al-Zahid S, Singh V: Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma. J Laryngol Otol; 2010 Jan;124(1):90-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma.
  • OBJECTIVE: We report an extremely rare presentation of concomitant tuberculous cervical lymphadenitis in a patient with carcinoma of the larynx.
  • CASE REPORT: A 66-year-old man presented with a nine-month history of hoarseness.
  • Biopsy of the vocal fold lesion revealed invasive squamous cell carcinoma.
  • The patient was treated with radiotherapy to the larynx and concomitant anti-tuberculosis chemotherapy.
  • Five months following treatment, there was no sign of laryngeal cancer recurrence; however, the patient continued to have a productive cough and night sweats.
  • CONCLUSION: To our knowledge, this is the first report of a laryngeal carcinoma with concurrent tuberculous cervical lymphadenitis.
  • In the face of an unhelpful fine needle aspiration cytology examination, an assumption of metastatic neck disease could have been made.
  • Subsequent surgical and/or oncological intervention would have been highly inappropriate, with potentially catastrophic effects.
  • This case highlights the importance of proper diagnosis, and emphasises the fact that tuberculosis should always be borne in mind in the differential diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Laryngeal Neoplasms / complications. Tuberculosis, Lymph Node / complications
  • [MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Biopsy. Humans. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Treatment Outcome. Vocal Cords / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646297.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


8. Morales-Puebla JM, Toro-Rojas M, Segura-Saint-Gerons R, Fanego-Fernández J, López-Villarejo P: Basaloid squamous cell carcinoma: report of five cases. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e451-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: report of five cases.
  • OBJECTIVES: To document the clinical and histopathological characteristics of basaloid squamous cell carcinoma (BSCC).
  • CASES: retrospective review of five cases with the diagnosis of BSCC of the larynx.
  • Surgery supplemented with radiation was used in three patients, partial surgery was used in another case and radiation and associated chemotherapy in the other one.
  • Two cases were found to have metastatic lymph nodes.
  • Central comedonecrosis within the cells nests, cell with nuclear palisading and high-grade dysplasia in overlaying mucosa are the main characteristics.
  • [MeSH-major] Carcinoma, Squamous Cell. Laryngeal Neoplasms
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038913.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


9. Chedid HM, Lehn CN, Rapoport A, Amar A, Franzi SA: Assessment of disease-free survival in patients with laryngeal squamous cell carcinoma treated with radiotherapy associated or not with chemotherapy. Braz J Otorhinolaryngol; 2010 Mar-Apr;76(2):225-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of disease-free survival in patients with laryngeal squamous cell carcinoma treated with radiotherapy associated or not with chemotherapy.
  • In early stage (I and II) laryngeal squamous cell carcinoma, both surgery and radiotherapy results in significant local and regional control.
  • In advanced tumors (III and IV), radiotherapy alone has local-regional control rates of 32-43%.
  • AIM: To assess disease-free survival in SCC laryngeal carcinoma patients submitted to radiotherapy alone and/or associated with chemotherapy.
  • MATERIALS AND METHODS: Retrospective study involving 84 cases of laryngeal SCC treated with radiotherapy or chemotherapy together with radiotherapy.
  • In the second group, 11 cases were EC III and 20 IV.
  • CONCLUSION: Disease-free survival of those patients submitted to radiotherapy because of laryngeal SCC was of 62.5%.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549084.001).
  • [ISSN] 1808-8686
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


10. Habl G, Jensen AD, Potthoff K, Uhl M, Hof H, Hajda J, Simon C, Debus J, Krempien R, Münter MW: Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. BMC Cancer; 2010;10:651
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
  • BACKGROUND: Primary treatment of carcinoma of the oro-/hypopharynx or larynx may consist of combined platinum-containing chemoradiotherapy.
  • In order to improve clinical outcome (i.e. local control/overall survival), combined therapy is intensified by the addition of the EGFR inhibitor cetuximab (Erbitux®).
  • Radiation therapy (RT) is carried out as intensity-modulated RT (IMRT) to avoid higher grade acute and late toxicity by sparing of surrounding normal tissues.
  • METHODS/DESIGN: The REACH study is a prospective phase II study combining chemoradiotherapy with carboplatin/5-Fluorouracil (5-FU) and the monoclonal epidermal growth factor-receptor (EGFR) antibody cetuximab (Erbitux®) as intensity-modulated radiation therapy in patients with locally advanced squamous-cell carcinomas of oropharynx, hypopharynx or larynx.Patients receive weekly chemotherapy infusions in the 1st and 5th week of RT.
  • Additionally, cetuximab is administered weekly throughout the treatment course.
  • IMRT is delivered as in a classical concomitant boost concept (bid from fraction 16) to a total dose of 69,9 Gy.
  • DISCUSSION: Primary endpoint of the trial is local-regional control (LRC).
  • Disease-free survival, progression-free survival, overall survival, toxicity, proteomic and genomic analyses are secondary endpoints.
  • The aim is to explore the efficacy as well as the safety and feasibility of this combined radioimmunchemotherapy in order to improve the outcome of patients with advanced head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Otorhinolaryngologic Neoplasms / therapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Cetuximab. Chemotherapy, Adjuvant. Disease-Free Survival. Fluorouracil / administration & dosage. Germany. Humans. Hypopharyngeal Neoplasms / therapy. Kaplan-Meier Estimate. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy. Prospective Studies. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71 [11483325.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4637-42 [8402640.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):450-6 [16303861.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Feb;5(2):79-81 [17344795.001]
  • [Cites] N Engl J Med. 2007 Aug 2;357(5):514-5 [17671265.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1872-3; author reply 1873 [17978301.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):166-71 [18977050.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • (PMID = 21108850.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN87356938
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3001721
  •  go-up   go-down


11. Sarkar S, Kundu AK, Chakrabarti S: Lungs: victim of synchronous double malignancies. J Assoc Physicians India; 2007 Mar;55:235-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 20 year young man was referred to our institution with superior vena cava (SVC) syndrome, multiple lung opacities and a mass lesion in the right upper zone (RUZ).
  • CT-guided FNAC from the mass lesion was consistent with the diagnosis of non-small cell lung carcinoma (NSCLC).
  • Both FNAC and excisional biopsy of the testicular mass confirmed the diagnosis of immature teratoma with choriocarcinoma, a form of non-seminomatous germ cell tumour (NSGCT).
  • With chemotherapy all metastatic lesions of lung and SVC syndrome disappeared, and the tumour-marker levels decreased.
  • However, the opacity in RUZ progessed to involve right recurrent laryngeal nerve at thoracic inlet, metastasized to the brain, and the patient expired after 4th cycle of chemotherapy.
  • [MeSH-major] Choriocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Humans. Male. Paraneoplastic Syndromes / etiology. Superior Vena Cava Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598338.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Prades JM, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP, Trombert B, Guerrier B: Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol; 2010;130(1):150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
  • CONCLUSIONS: Conventional radiotherapy with concurrent cisplatin is significantly superior to induction cisplatin fluorouracil chemotherapy followed by radiotherapy in terms of laryngeal preservation in patients with T3 hypopharyngeal carcinoma.
  • Despite a high rate of laryngeal preservation no survival benefit was recorded in this selected population.
  • OBJECTIVES: To compare conventional radiotherapy with concurrent cisplatin to induction chemotherapy with cisplatin fluorouracil followed by conventional radiotherapy.
  • The primary end point was the preservation of the larynx.
  • The secondary end points included toxicity, causes of death, and survival rates.
  • PATIENTS AND METHODS: Seventy-one adult patients with previously untreated resectable T3 pyriform sinus squamous cell carcinoma were enrolled in the multicenter prospective randomized phase III trial.
  • RESULTS: The rates of laryngeal preservation at 2 years were 68% for the induction chemotherapy (IC) group and 92% for the chemoradiotherapy (CR) group (p = 0.016).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Neoadjuvant Therapy. Pyriform Sinus
  • [MeSH-minor] Cause of Death. Combined Modality Therapy. Disease-Free Survival. Humans. Laryngectomy. Neoplasm Staging. Prognosis. Prospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449227.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Taillade L, Alexandre I, Billemont B, Meric JB, Sultan-Amar V, Rixe O: [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma]. Bull Cancer; 2009;96 Suppl 1:S45-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
  • [Transliterated title] L'angiogenèse: une nouvelle cible thérapeutique des cancers thoraciques et ORL.
  • Angiogenesis or new blood vessel formation is a complex and fundamental event in the process of tumor growth and metastatic dissemination.
  • These molecules directly inhibit VEGF or the kinase activity of its receptor (VEGFR) and represent a significant therapeutic progress in several solid tumors types.
  • First clinical studies of antiangiogenic agents in thoracic and laryngopharyngeal carcinomas have shown promise mainly in combination with other therapies (chemotherapy, other targeted therapies or radiotherapy).
  • Besides common antiangiogenic therapies-induced adverse events, risks of bleeding caused by tumor necrosis mainly in squamous cell lung carcinomas have been observed during early clinical trials.
  • Assessment of surrogate markers of target inhibition could allow a better selection of patients able to benefit from antiangiogenic treatments eventually combined with chemotherapy or molecules targeting others metabolic pathways.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Lung Neoplasms / blood supply. Neovascularization, Pathologic / drug therapy. Otorhinolaryngologic Neoplasms / blood supply. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Laryngeal Neoplasms / blood supply. Laryngeal Neoplasms / drug therapy. Mesothelioma / blood supply. Mesothelioma / drug therapy. Pharyngeal Neoplasms / blood supply. Pharyngeal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433373.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 49
  •  go-up   go-down


14. Rózga A, Kurnatowska AJ, Raczyńsak-Witońska G, Loga G: [Evalution of activity of acid aspartic proteinase in Candida strains isolated from oral cavity of patients with increased risk of mycosis]. Wiad Parazytol; 2001;47(4):883-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first group comprised patients with cancer of the larynx qualified for surgery, the second- patients with neoplastic disease ( Hodgkin s disease, lymphoma, acute granulocytic leukaemia, lymphatic leukaemia, lung cancer, multiple myeloma, stomach cancer, breast cancer) who were not treated, the third group- patients with neoplastic diseases treated by chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886442.001).
  • [ISSN] 0043-5163
  • [Journal-full-title] Wiadomości parazytologiczne
  • [ISO-abbreviation] Wiad Parazytol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 3.4.23.- / Aspartic Acid Endopeptidases
  •  go-up   go-down


15. Issing WJ: [Gastroesophageal reflux -- a common illness?]. Laryngorhinootologie; 2003 Feb;82(2):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a long time heartburn was not considered a symptom for serious illness.
  • By now, however, it is accepted that the incidence of secondary carcinoma of the esophagus caused by chronic GERD has increased dramatically since the nineteen-seventies.
  • Mechanisms leading to GERD are complex and its incidence is not necessarily pathological.
  • Laryngopharyngeal reflux (LPR) often results in atypical manifestations with oral, pharyngeal, laryngeal, and pulmonary disorders.
  • Laryngopharyngeal reflux is known to contribute to posterior acid laryngitis and laryngeal contact ulceration or granuloma formation, laryngeal cancer, chronic hoarseness, pharyngitis, asthma, pneumonia, nocturnal choking, and dental diseases.
  • Today, PPI are the medication of choice in both acute and long-term (prophylactic) therapy of GERD.
  • The so called "step-up-strategy" of medication is no longer recommended.
  • Only in the case of persisting symptoms medication was further increased to high-dose PPI therapy.
  • In the past this increase in medication lead to a prolonged healing process and consequently to higher medication costs.
  • Studies have shown that a "step-down"-therapy, beginning with high dose PPI, is highly preferable, since it is much more effective.
  • Depending on the degree of the symptoms, however, medication may also be applied "on-demand".
  • The BfArM has approved this kind of medication application only for Esomeprazol (Nexium mups 20 mg).
  • [MeSH-minor] Anti-Ulcer Agents / administration & dosage. Cross-Sectional Studies. Humans. Incidence. Laryngitis / drug therapy. Laryngitis / epidemiology. Laryngitis / etiology. Proton Pump Inhibitors


16. Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, Hareyama M, Takada T, Karasawa K, Watanabe T, Yorozu A, Tachibana H, Suzuki G, Hayabuchi N, Toba T, Yamada S: Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1045-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy.
  • PURPOSE: To analyze the outcomes of patients with early hypopharyngeal cancer treated with radical radiotherapy (RT).
  • METHODS AND MATERIALS: Ten institutions combined the data from 115 patients with Stage I-II hypopharyngeal squamous cell carcinoma treated with definitive RT between 1990 and 2001.
  • Conventional fractionation was used in 98 patients and twice-daily RT in 17 patients; chemotherapy was combined with RT in 57 patients.
  • Of the 115 patients, local control with laryngeal voice preservation was achieved in 34 of 39 patients with T1 lesions, including 7 patients successfully salvaged, and in 56 of 76 patients with T2 lesions.
  • Of the 115 patients, 19 died of hypopharyngeal cancer, 10 died of second primary cancers, and 14 died of other causes during the study and follow-up periods.
  • CONCLUSIONS: Patients with early hypopharyngeal cancer tended to have a good prognosis after RT.
  • However, second malignancies had an adverse effect on the overall outcomes of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Radiotherapy Dosage. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682142.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, Lucas P: Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit; 2005 Sep;11(9):RA279-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy.
  • Over the past 40 years, hyperbaric oxygen (HBO2) therapy has been recommended and used in a wide variety of medical conditions.
  • In the 1950s, HBO2 was first used as a treatment, in addition to radiation, for head and neck cancers and cervical cancer.
  • Many studies have been conducted to investigate possible therapeutic effects HBO2 as part of cancer management.
  • Evidences showed that HBO2 improved tumor oxygenation, and treatment with HBO2 during irradiation has been shown to improve the radiation response of many solid tumors.
  • It was used for delayed radiation injuries for soft tissue and bony injuries, for symptomatic radiation reactions of the urinary bladder and the bowel, for laryngeal radionecrosis, for radiation-induced optic neuropathy, for radiation-induced proctitis and for radiation-induced necrosis of the brain.
  • HBO2 also increases sensitivity to chemotherapy.
  • A significant improvement in tumor response was obtained when photodynamic therapy (PDT) was delivered during hyperoxygenation.
  • The possibility of combining HBO2, PDT and photosensitizers to overcome primary and secondary carcinoma deserve extensive laboratory and clinical research works.
  • HBO2 is a relatively benign with few contraindications, even for active cancer patients.
  • [MeSH-major] Hyperbaric Oxygenation. Neoplasms / therapy
  • [MeSH-minor] Anemia / complications. Anemia / therapy. Anoxia / complications. Anoxia / therapy. Combined Modality Therapy. Female. Humans. Male. Phototherapy. Radiation Injuries / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127374.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 103
  •  go-up   go-down


18. Camacho LH: Clinical applications of retinoids in cancer medicine. J Biol Regul Homeost Agents; 2003 Jan-Mar;17(1):98-114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applications of retinoids in cancer medicine.
  • The most extensively studied agents in cancer medicine include all-trans-retinoic acid, 9-cis-retinoic acid, and 13-cis-retinoic acid.
  • In addition to several described immune regulatory functions, these agents may exert their antineoplastic effects through the regulation of tumor suppressor genes such as RAR-beta2.
  • The survival benefit provided to patients with acute promyelocytic leukemia (APL) after induction therapy with all-trans RA and the responses experienced by patients with cutaneous lesions from Kaposi's sarcoma and cutaneous T cell lymphoma treated with 9-cis RA and a selective rexinoid--bexarotene--respectively, led to their approval by the Food and Drug Administration during the last decade.
  • As chemopreventive agents, retinoids have proven to effectively regress laryngeal papillomatosis and oral leukoplakia lesions.
  • The ability of 13-cis-RA to prevent second primary malignancies in patients with carcinoma of the head and neck has also been demonstrated.
  • Unfortunately, this intervention did not affect the primary tumor recurrence rates.
  • The toxicity and efficacy of retinoids administered in combination with other biological and cytotoxic agents have also been explored in patients with renal cell carcinoma, breast cancer, myelodysplasia, prostate, cervix, and other malignancies with a broad range of reported responses.
  • Further characterization of the molecular processes modulated by these agents will serve to better define their role in the prevention and treatment of human cancer and to tailor specific targeted therapies in combination with other compounds.
  • [MeSH-major] Neoplasms / drug therapy. Retinoids / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptors, Retinoic Acid / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12757024.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoids
  • [Number-of-references] 167
  •  go-up   go-down


19. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Germann N, Tubiana-Mathieu N: Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol; 2007 Jun;30(3):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
  • OBJECTIVES: This phase II study was conducted to assess the efficacy of docetaxel plus gemcitabine in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: Forty patients with pharynx or larynx cancer were included and treated with an intravenous infusion of docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 day 1 and day 8 every 3 weeks for 6 cycles.
  • RESULTS: Among the 40 patients included, 17 had metastatic disease and 18 had received prior chemotherapy.
  • Three treatment-related deaths due to infection were reported.
  • CONCLUSION: The docetaxel and gemcitabine combination is an active treatment of recurrent or metastatic head and neck cancer.
  • However, this regimen is associated with a high hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Laryngeal Neoplasms / drug therapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Recurrence. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551305.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Miura K, Kum Y, Han G, Tsutsui Y: Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature. Pathol Int; 2003 Oct;53(10):710-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature.
  • Primary laryngeal angiosarcoma (LA) is quite rare with only 13 cases reported in English literature to date.
  • A case of LA after radiation therapy for tuberculosis and squamous cell carcinoma is reported.
  • A 70-year-old woman had a history of radiation therapy for left cervical tuberculosis at the age of 28.
  • At 60 years of age a squamous cell carcinoma of the larynx was found and chemotherapy and radiotherapy, consisting of a total dose of 68.4 Gy, were administered.
  • At the age of 68, recurrent squamous cell carcinoma was suspected from several biopsies, and a total laryngectomy with right thyroidectomy was performed.
  • The tumor cells formed vascular spaces and expressed some endothelial markers, such as CD34, CD31, and Ulex europaeus agglutinin I, but no epithelial markers, such as cytokeratins or epithelial membrane antigen.
  • No residual squamous cell carcinoma was found.
  • In the present case, it was suspected that irradiation to the larynx for cervical tuberculosis and squamous cell carcinoma induced angiosarcoma.
  • The patient was still alive despite multiple skin and soft tissue metastasis 3 years and 6 months after the radical operation.
  • Distinction of postirradiation angiosarcoma from pseudoangiosarcomatous carcinoma seems difficult but is important because irradiation is not effective and an initial radical surgery is the only effective treatment.
  • Although irradiation is a common treatment for laryngeal squamous cell carcinoma, this is only the second case of radiation-induced LA in English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Hemangiosarcoma / etiology. Laryngeal Neoplasms / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Tuberculosis, Lymph Node / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Laryngectomy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516323.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


21. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G: Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol; 2001 Jun;24(3):227-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
  • The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).
  • Secondary endpoints included preliminary assessment of response.
  • Patients with locally advanced HNC, a World Health Organization performance status 0 to 2, and no prior history of chemotherapy or radiotherapy were included.
  • Treatment consisted of docetaxel 80 mg/m2 (1-hour infusion) on day 1, cisplatin 40 mg/m2 (1-hour infusion) on days 2 and 3, and 5-fluorouracil 1,000 mg/m2 (24-hour continuous infusion), on days 1 to 3, repeated every 28 days for a maximum of 4 cycles per patient.
  • Radiation therapy (RT) to the primary tumor site and neck lymph nodes was planned within 5 weeks of the last cycle of chemotherapy.
  • The primary tumor site received 60 to 70 Gy.
  • The most common acute nonhematologic toxicities from DCF induction chemotherapy included alopecia, mucositis, peripheral sensory neuropathy, onycholysis, and asthenia.
  • Febrile neutropenia developed in two patients and grade IV diarrhea in one patient.
  • There were no treatment-related deaths.
  • The overall response rate (RR) after DCF induction chemotherapy was 90% (95% confidence interval [CI]: 76.8-103.1%).
  • After the completion of RT, the overall RR was 95% with a complete response rate of 73% (95% CI: 49.9-90.1%).
  • Organ preservation was achieved in eight patients with laryngeal cancer and one patient with base of tongue involvement.
  • Sequential chemoradiotherapy with DCF and growth factor support is feasible and very active, with durable responses in patients with locally advanced head and neck cancer.
  • Further evaluation of this modality is justified in the context of a clinical trial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Taxoids
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404490.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Paludetti G, Almadori G, Bussu F, Galli J, Cadoni G, Maurizi M: Hypofolatemia as a risk factor for head and neck cancer. Adv Otorhinolaryngol; 2005;62:12-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofolatemia as a risk factor for head and neck cancer.
  • Head and neck cancer (HNSCC) includes squamous cell carcinomas of the oral cavity, pharynx and larynx.
  • The standard therapeutic approach, focused on surgery, irradiation and chemotherapy, alone or in combination, has been in part modified in the last 30 years, but the overall survival of HNSCC patients has not substantially improved.
  • To characterize and thus identify high-risk mucosal areas and preclinical tumors, molecular abnormalities in head and neck carcinogenesis have been extensively studied.
  • Nevertheless, we know that metabolic alterations, often aspecific, are frequently associated with cancer.
  • These may be secondary or may precede tumor development and favorite progression.
  • Homocysteine levels in cancer patients are probably largely affected by the HNSCC phenotype.
  • An accumulation of homocysteine might reveal a genetic defect which is theoretically a target for pharmacological therapy, for example by antifolic drugs.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Glutamate Carboxypeptidase II / blood. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Homocysteine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy, Needle. Case-Control Studies. Cohort Studies. Female. Humans. Immunohistochemistry. Italy / epidemiology. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Neoplasm Staging. Prognosis. Reference Values. Risk Factors. Sensitivity and Specificity. Smoking / adverse effects. Smoking / epidemiology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608414.001).
  • [ISSN] 0065-3071
  • [Journal-full-title] Advances in oto-rhino-laryngology
  • [ISO-abbreviation] Adv. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0LVT1QZ0BA / Homocysteine; EC 3.4.17.21 / Glutamate Carboxypeptidase II
  •  go-up   go-down


23. Chen W, Guo X, Luan X, Zhang C: [Long-term follow-up observation of clinical therapy for laryngeal carcinoma recurrence and cervical metastasis]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2004 Sep;18(9):536-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term follow-up observation of clinical therapy for laryngeal carcinoma recurrence and cervical metastasis].
  • OBJECTIVE: To observe the long-term effects of clinical treatment for laryngeal carcinoma recurrence and cervical metastasis, and discuss the operative therapy method for laryngeal carcinoma recurrence and cervical metastasis.
  • METHOD: Retrospective analysis the 70 patients with laryngeal carcinoma recurrence and cervical metastasis who was cured in our hospital from 1990 to 1998, including 31 local recurrence, 15 stomal recurrence and 24 cervical lymph node metastasis.
  • Twenty-eight patients who received the second-time operation survived over 5 years.
  • In 31 patients with local recurrence, 19 patients received total laryngectomy and 15 patients of them are now living, but 12 patients who did not accept surgical therapy were died in 1-3 years separately; 9 patients with stomal recurrence received the second-time operation and 5 of them lived 5 years longer, however, the 6 patients with stomal recurrence who did not accept the second-time operation all died in 18 months; In 24 patients with cervical lymph node metastasis, 15 patients received the neck dissection and 8 of them are now alive, but the rest patients who did not accept the operation died in 2 years.
  • CONCLUSION: Regular re-examination and systemic clinical follow-up studying are very important for early detection and early treatment in laryngeal carcinoma recurrence and cervical metastasis; Second-time surgical operation is an effective therapeutic method for laryngeal carcinoma recurrence and cervical metastasis; Radiotherapy and chemotherapy play a limited role in clinical therapy for laryngeal carcinoma recurrence and cervical metastasis.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Retrospective Studies

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696949.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Durdux C: [Cisplatin and derivatives with radiation therapy: for what clinical use?]. Cancer Radiother; 2004 Nov;8 Suppl 1:S88-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cisplatin and derivatives with radiation therapy: for what clinical use?].
  • [Transliterated title] Sels de platine et radiothérapie: vingt ans de pratique.
  • The first part of this overview will describe biological mechanisms of interaction between radiation therapy and platinum derivatives.
  • The second part will report the major clinical impact of their association.
  • [MeSH-major] Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Anus Neoplasms / drug therapy. Anus Neoplasms / mortality. Anus Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / radiotherapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Leukemia P388 / drug therapy. Leukemia P388 / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / radiotherapy. Male. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / radiotherapy. Meta-Analysis as Topic. Mice. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Rats. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Time Factors. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679253.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Radiation-Sensitizing Agents; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 71
  •  go-up   go-down


25. Ishii K, Tashiro M, Hosono M, Fukuda H, Takada Y, Kondo S, Inoue Y, Iguchi H, Kusuki M, Yamane H: Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer. Acta Otolaryngol Suppl; 2004 Oct;(554):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
  • OBJECTIVE: This study was conducted to evaluate the efficacy and feasibility of our accelerated hyperfractionation with concomitant boost for stage II laryngeal cancer and stages III-IVb locally advanced head and neck cancer.
  • PATIENTS AND METHODS: From January 2000 to October 2001, eight patients with AJCC 1998 stage II laryngeal cancer and 11 patients with AJCC 1998 stages III-IVb locally advanced head and neck cancer underwent accelerated hyperfractionated radiation therapy.
  • For the stage II laryngeal cancer, radiation was delivered at a 2.0 Gy fraction a day, 5 fractions per week for the first 3 weeks, then 2 fractions (1.8 and 1.2 Gy) a day, 5 times a week for 2.5 weeks, with total dose of 69 Gy.
  • For stages III-IVb head and neck cancer, radiation was given at a 1.8 Gy fraction a day, 5 fractions per week for 6 weeks and a boost was added up to 70.5 Gy with 1.5 Gy as a second daily fraction during the last 2.2 weeks.
  • Among the patients, 16 (84%) received concomitant chemotherapy, mainly with low-dose carboplatin.
  • Acute toxicity based on RTOG criteria and tumor response at 1 month post-treatment were estimated as initial effects.
  • RESULTS: The overall response rate was 100% in patients with stage II laryngeal cancer and 91% in patients with stages III and IVb head and neck cancer.
  • Eighteen patients (95%) completed radiation therapy without interruption related to acute side effects, while one had prolongation of the treatment for more than 1 week because of neutropenia.
  • CONCLUSIONS: Our results demonstrated that accelerated hyperfractionation, mostly combined with concomitant chemotherapy, had a good overall response rate with acceptable toxicity in stage II laryngeal cancers and stages III-IVb head and neck tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Head and Neck Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15513514.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


26. Bessède JP, Vinh D, Genet D, Khalifa N, Aubry K, Rhein B, Orsel S, Tubiana-Mathieu N, Clavère P: [Induction chemotherapy and laryngeal preservation in pharyngolaryngeal carcinomas. Study of a 124 serie's patients and patient's follow up with laryngeal preservation]. Rev Laryngol Otol Rhinol (Bord); 2004;125(2):81-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and laryngeal preservation in pharyngolaryngeal carcinomas. Study of a 124 serie's patients and patient's follow up with laryngeal preservation].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée dans les cancers du pharyngolarynx. Etude d'une série de 124 patients et suivi des patients en préservation laryngée.
  • OBJECTIVE: To try and determine the value of chemotherapy and its subsequent effect on laryngeal preservation in patients presenting with laryngeal and pharyngeal carcinomas.
  • The second group was treated with chemotherapy and subsequent salvage surgery and/or radiotherapy.
  • Their survival rates and laryngeal preservation rates were compared.
  • PATIENTS AND METHODS: From 251 patients the authors have retrospectively studied 124 patients with induction chemotherapy.
  • The survival rate has been compared with a control group of 127 patients who was treated by initial surgery and radiotherapy.
  • The survival for patients with a total clinical response following chemotherapy was 49.8% at 5 years.
  • Survival with no total clinical response following chemotherapy treated by secondary radiotherapy was 25.7% at 3 years.
  • The initial rate of laryngeal preservation is 32.2% but this rate fell to 22% after local recurrencies.
  • CONCLUSION: The group with total clinical response after induction chemotherapy with laryngeal preservation have a non significantly difference in their survival compared with the group initially treated by surgery and radiotherapy.
  • The rate of local recurrency of patients with laryngeal preservation is 32.5% and gives a finally rate of laryngeal preservation of 21%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Larynx / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462166.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Silveira NJ, Varuzza L, Machado-Lima A, Lauretto MS, Pinheiro DG, Rodrigues RV, Severino P, Nobrega FG, Head and Neck Genome Project GENCAPO, Silva WA Jr, de B Pereira CA, Tajara EH: Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genomics; 2008;1:56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries.
  • BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies in humans.
  • When detected early, HNSCC has a good prognosis, but most patients present metastatic disease at the time of diagnosis, which significantly reduces survival rate.
  • METHODS: Aiming to identify differentially-expressed genes involved in laryngeal squamous cell carcinoma (LSCC) development and progression, we generated individual Serial Analysis of Gene Expression (SAGE) libraries from a metastatic and non-metastatic larynx carcinoma, as well as from a normal larynx mucosa sample.
  • RESULTS: Statistical data analysis identified a subset of 1,216 differentially expressed tags between tumor and normal libraries, and 894 differentially expressed tags between metastatic and non-metastatic carcinomas.
  • Three genes displaying differential regulation, one down-regulated (KRT31) and two up-regulated (BST2, MFAP2), as well as one with a non-significant differential expression pattern (GNA15) in our SAGE data were selected for real-time polymerase chain reaction (PCR) in a set of HNSCC samples.
  • Consistent with our statistical analysis, quantitative PCR confirmed the upregulation of BST2 and MFAP2 and the downregulation of KRT31 when samples of HNSCC were compared to tumor-free surgical margins.
  • As expected, GNA15 presented a non-significant differential expression pattern when tumor samples were compared to normal tissues.
  • CONCLUSION: To the best of our knowledge, this is the first study reporting SAGE data in head and neck squamous cell tumors.
  • Statistical analysis was effective in identifying differentially expressed genes reportedly involved in cancer development.
  • The differential expression of a subset of genes was confirmed in additional larynx carcinoma samples and in carcinomas from a distinct head and neck subsite.
  • This result suggests the existence of potential common biomarkers for prognosis and targeted-therapy development in this heterogeneous type of tumor.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1244-51 [15558013.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):789-97 [15499618.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):127-35 [15685196.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):182-6 [15640797.001]
  • [Cites] Physiol Genomics. 2002 Oct 29;11(2):37-44 [12407185.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):619-30 [11489919.001]
  • [Cites] Head Neck. 2001 Mar;23(3):238-53 [11428456.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):977-82 [11359384.001]
  • [Cites] Bioinformatics. 2000 Nov;16(11):953-9 [11159306.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):921-8 [10953016.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3220-4 [10918578.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):374-81 [10718422.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):151-68 [15657362.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8 [15655179.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8442-50 [15623624.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Dec;4(8):637-51 [15578920.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3697-704 [15292061.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 [10329429.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Nature. 1993 Dec 2;366(6454):473-5 [7902537.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):249-58 [15352037.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):89-96 [15221650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cell Mol Life Sci. 2004 Jun;61(11):1372-83 [15170515.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2484-98 [14676830.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):295-302 [15023835.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):418-26 [14969821.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):55-63 [14729608.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):429-35 [12964014.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3058-64 [12912957.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):760-70 [12874079.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):683-9 [12866027.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):259-68 [12618198.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):248-58 [12618197.001]
  • [Cites] Eur J Oral Sci. 2003 Feb;111(1):34-41 [12558806.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):159-62 [12429865.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8206-19 [12444558.001]
  • [Cites] Biol Direct. 2008;3:22 [18513408.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1482-94 [12237917.001]
  • [Cites] Head Neck. 2002 Sep;24(9):874-87 [12211052.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2634-40 [11965536.001]
  • [Cites] Cell Growth Differ. 2002 Apr;13(4):163-71 [11971816.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1184-90 [11861402.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6196-204 [11593428.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Hum Mol Genet. 2001 Sep 15;10(19):2133-41 [11590130.001]
  • [Cites] Cell Oncol. 2008;30(1):63-75 [18219111.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1971-82 [17043662.001]
  • [Cites] Biol Cell. 2006 Aug;98(8):479-90 [16608439.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):136-43 [16181731.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2860-8 [16574107.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10089-97 [16492672.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1024-39 [16205657.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Oral Oncol. 2005 Apr;41(4):365-74 [15792608.001]
  • (PMID = 19014460.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2629771
  • [Investigator] Curry PM; de Carvalho MB; Dias-Neto E; Figueiredo DL; Fukuyama EE; Góis-Filho JF; Leopoldino AM; Mamede RC; Michaluart-Junior P; Moreira-Filho CA; Moyses RA; Nóbrega FG; Nóbrega MP; Nunes FD; Ojopi EP; Okamoto OK; Serafini LN; Severino P; Silva AM; Silva WA Jr; Silveira NJ; Souza SC; Tajara EH; Wünsch-Filho V; Zago MA; Amar A; Arap SS; Araújo NS; Araújo-Filho V; Barbieri RB; Bandeira CM; Bastos AU; Braconi MA; Brandão LG; Brandão RM; Canto AL; Carmona-Raphe J; Carvalho-Neto PB; Casemiro AF; Cerione M; Cernea CR; Cicco R; Chagas MJ; Chedid H; Chiappini PB; Correia LA; Costa A; Costa AC; Cunha BR; Curioni OA; Dias TH; Durazzo M; Ferraz AR; Figueiredo RO; Fortes CS; Franzi SA; Frizzera AP; Gallo J; Gazito D; Guimarães PE; Gutierres AP; Inamine R; Kaneto CM; Lehn CN; López RV; Macarenco R; Magalhães RP; Martins AE; Meneses C; Mercante AM; Montenegro FL; Pinheiro DG; Polachini GM; Porsani AF; Rapoport A; Rodini CO; Rodrigues AN; Rodrigues-Lisoni FC; Rodrigues RV; Rossi L; Santos AR; Santos M; Settani F; Silva FA; Silva IT; Silva-Filho GB; Smith RB; Souza TB; Stabenow E; Takamori JT; Tavares MR; Turcano R; Valentim PJ; Vidotto A; Volpi EM; Xavier FC; Yamagushi F; Cominato ML; Correa PM; Mendes GS; Paiva R; Ramos O; Silva C; Silva MJ; Tarlá MV
  •  go-up   go-down


28. Nakamura K, Shioyama Y, Sasaki T, Ohga S, Saku M, Urashima Y, Yoshitake T, Nakashima T, Kuratomi Y, Komune S, Terashima H, Honda H: Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):680-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx.
  • PURPOSE: Early squamous cell carcinoma of the hypopharynx is a rare clinical entity.
  • Our objective was to analyze the outcome of patients with early hypopharyngeal cancer treated with curative radiotherapy or the combination of preoperative radiotherapy with surgery.
  • METHODS AND MATERIALS: Forty-three patients with Stage I-II hypopharyngeal cancer were initially treated with 30-40 Gy of irradiation with or without chemotherapy.
  • Thirty-two patients (74.4%) who demonstrated a complete response continued to receive further radiotherapy, with a median total dose of 61.2 Gy.
  • RESULTS: Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with Stage I disease, and in 23 (67.6%) of 34 patients with Stage II disease.
  • Four patients died of hypopharyngeal cancer, and 5 died of second-primary esophageal cancer.
  • CONCLUSIONS: A majority of patients with early hypopharyngeal cancer was curable.
  • However, second malignancies influenced the overall outcome of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Pharyngectomy. Radiotherapy Dosage. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936545.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Laccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H: Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer; 2001 Sep 15;92(6):1504-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
  • BACKGROUND: The current studies documented the results achieved with chemotherapy alone with curative intent in a series of 67 patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders after a platin-based induction chemotherapy regimen.
  • A minimum of 3 years of follow-up was achieved.
  • Statistical analyses of survival, local control, lymph node control, distant metastasis, and second primary tumor rates were based on the Kaplan-Meier life-table method.
  • Laryngeal preservation rates and local control rates are presented.
  • The 5-year actuarial local control estimate was 65.7% in Group I patients and 37.5% in Group II patients.
  • Local control rates after salvage treatment were 100% in Group I patients and 83% in Group II patients.
  • Laryngeal preservation rates after salvage treatment were 100% in Group I patients and 64% in Group II patients.
  • The 5-year actuarial lymph node control estimate was 90% in Group I patients and 73.7% in Group II patients.
  • The 10-year actuarial estimate for patients without metachronous second primary tumors was 56.4% in Group I and 46.1% in Group II.
  • CONCLUSIONS: The current report 1) contradicts the old dogma of nonchemocurability for invasive squamous cell carcinoma of the upper aerodigestive tract and 2) suggests that the use of a platin-based chemotherapy-alone regimen with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx who are classified as T1-T4N0M0 complete clinical responders after receiving an induction chemotherapy regimen is best indicated when the tumor originates from the glottis.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Second Primary. Platinum / administration & dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745228.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 49DFR088MY / Platinum; U3P01618RT / Fluorouracil
  •  go-up   go-down


30. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • RESULTS: After combined application of MMC and surgical intervention in cases of recurrent stenosising processes in head and neck organs, especially the larynx and the trachea, a sustained improvement was achieved in the pre-operative stenosis level as well as in the pre-operative, severely limited, forced inspiratory volume in 1 second (F1V1).
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • During the 10 years in which it was used, the clinical findings confirmed an enhancement in the containment of complex cases without the occurrence of any complications.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


31. Gao X, Fisher SG, Mohideen N, Emami B: Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys; 2003 Jun 1;56(2):427-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers in patients with laryngeal cancer: a population-based study.
  • BACKGROUND: Literature regarding incidence of site-specific second cancers after laryngeal cancer is limited.
  • Risk factors associated with second primaries are unknown.
  • METHODS: Second primaries after laryngeal cancer in the SEER database (1973-1996) were analyzed for incidence, relative risk compared with the general population, and potential risk factors, including radiotherapy.
  • Information on chemotherapy and tobacco smoking was not available in the SEER database.
  • RESULTS: Of 20,074 laryngeal cancer patients surviving at least 3 months, 3533 (17.6%) developed second cancers.
  • The cumulative risk of developing a second cancer was 26% at 10 years and 47% at 20 years.
  • Compared with age-adjusted, gender, and tumor-specific rates in the general population, laryngeal cancer patients had higher risks of second cancers overall (observed-to-expected ratio [O/E] = 1.68, 95% confidence interval [CI] = 1.58-1.79), head-and-neck (4.81 [4.31-5.58]), esophageal (3.99 [3.29-4.83]), and lung (3.56 [3.34-3.79]) cancer.
  • Advanced age at initial diagnosis was associated with increased risks of second cancers (p = 0.0001).
  • Radiotherapy was associated with increased risk of second cancers overall (relative risk [RR] = 1.10 [1.02-1.18], p = 0.012), especially second cancers of the lung (RR = 1.18, [1.05-1.33], p = 0.006) and possibly second cancers of the head and neck (RR = 1.26, [0.99-1.60], p = 0.061).
  • Radiotherapy was associated with a 68% excess risk (RR = 1.68, [1.16-2.43], p = 0.007) of developing a second head-and-neck cancer in patients who survived more than 5 years.
  • Second primary was associated with a poor survival (p = 0.0001).
  • CONCLUSIONS: Second cancers after laryngeal cancer are common, especially for long-term survivors.
  • Radiotherapy was associated with a small increased risk of developing second cancers overall and long-term risk of head-and-neck cancers.
  • This data should be interpreted with caution in light of the lack of information on chemotherapy and tobacco smoking in the SEER database.
  • Prevention and early detection are indicated.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Laryngeal Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Analysis of Variance. Confidence Intervals. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Risk. Survival Rate. Survivors

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738317.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Tejedor M, Valerdi JJ, Arias F, Dominguez MA, Pruja E, Mendez L, Illarramendi JJ: Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma. Cytokines Cell Mol Ther; 2000 Mar;6(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma.
  • An open-label, non-randomized study evaluated the feasibility and efficacy of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r-metHuG-CSF) to prevent mucositis induced by accelerated hyperfractionated radiotherapy (1.6 Gy b.i.d., total dose 67.2 Gy in six weeks with a two-week split) and concomitant chemotherapy (cisplatin, 20 mg/m2/day, days 1-5 by continuous intravenous infusion) in patients with laryngeal carcinoma.
  • Filgrastim 300 microg/day was administered on days 1, 3, and 5 in weeks 2-6 of radiotherapy, after the second fraction.
  • Nineteen patients (95%) completed the treatment in the planned time.
  • The administration of filgrastim with this regimen was feasible, and it appeared to reduce the severity and duration of mucositis induced by the combined treatment.
  • [MeSH-major] Cisplatin / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Laryngeal Neoplasms / therapy. Mouth Mucosa / radiation effects. Radiation Injuries / prevention & control. Stomatitis / prevention & control
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Filgrastim. Humans. Infusions, Intravenous. Male. Middle Aged. Recombinant Proteins. Survival Rate

  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976537.001).
  • [ISSN] 1368-4736
  • [Journal-full-title] Cytokines, cellular & molecular therapy
  • [ISO-abbreviation] Cytokines Cell. Mol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Dequanter D, Lothaire P: The role of salvage surgery in organ preservation strategies in advanced head and neck cancer. B-ENT; 2008;4(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of salvage surgery in organ preservation strategies in advanced head and neck cancer.
  • It is now established that head & neck squamous cell carcinomas represent a major group of tumours for which an improvement in the overall survival rate could be achieved by a multimodality approach.
  • Surgery as salvage treatment also continues to play an important role in organ preservation strategies in advanced head and neck cancer.
  • METHODS: Before the prospective randomised organ preservation trial conducted by the Department of Veterans Affairs Laryngeal Cancer Study Group demonstrating the benefits of induction chemotherapy, the standard of care for most advanced laryngeal/pharyngo-laryngeal carcinomas was total laryngectomy/pharyngo-laryngectomy and postoperative radiotherapy.
  • The new approach was also supported by a similar prospective trial from the EORTC Head & Neck Cooperative Group dealing with advanced hypopharyngeal squamous cell carcinomas.
  • Currently, advanced laryngeal/pharyngo-laryngeal carcinomas are treated with chemoradiotherapy but some patients will require a more complex salvage laryngectomy/pharyngo-laryngectomy.
  • RESULTS: In a first group of 44 patients treated with sequential chemotherapy and radiotherapy, median survival was 6.7 years.
  • 20/44 (50%) of patients retained their larynx.
  • Only 5 patients needed complex salvage surgery.
  • In the second group of 19 patients who received concomitant chemoradiotherapy, 78.9% of the patients retained their larynx.
  • CONCLUSION: CTx and RT is an effective strategy for organ preservation without compromising the survival of patients with locally advanced pharyngo-laryngeal carcinoma, keeping surgery for salvage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Salvage Therapy / methods
  • [MeSH-minor] Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681202.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Belgium
  •  go-up   go-down


34. Bogo D, de Matos MF, Honda NK, Pontes EC, Oguma PM, da Santos EC, de Carvalho JE, Nomizo A: In vitro antitumour activity of orsellinates. Z Naturforsch C; 2010 Jan-Feb;65(1-2):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the anticancer activity of lecanoric acid, a secondary metabolite of the lichen Parmotrema tinctorum, and its derivatives, orsellinates, obtained by structural modification.
  • A cytotoxicity assay was carried out in vitro with sulforhodamine B (SRB) using HEp-2 larynx carcinoma, MCF7 breast carcinoma, 786-0 kidney carcinoma, and B16-F10 murine melanoma cell lines, in addition to a normal (Vero) cell line in order to calculate the selectivity index of the compounds. n-Butyl orsellinate was the most active compound, with IC50 values (the concentration that inhibits 50% of growth) ranging from 7.2 to 14.0 microg/mL, against all the cell lines tested.
  • The compound was more active (IC50 = 11.4 microg/mL) against B16-F10 cells than was cisplatin (12.5 microg/mL).
  • Conversely, lecanoric acid and methyl orsellinate were less active against all cell lines, having an IC50 value higher than 50 microg/mL.
  • Ethyl orsellinate was more active against HEp-2 than against MCF7, 786-0, or B16-F10 cells.
  • The same pattern was observed for n-propyl and n-butyl orsellinates. n-Pentyl orsellinate was less active than n-propyl or n-butyl orsellinates against HEp-2 cells.
  • The orsellinate activity increased with chain elongation (from methyl to n-butyl), a likely consequence of an increase in lipophilicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Resorcinols / therapeutic use. Salicylates / therapeutic use. Vero Cells / drug effects
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cell Adhesion. Cell Line, Tumor. Cercopithecus aethiops. Female. History, Medieval. Humans. Melanoma, Experimental / drug therapy. Models, Molecular

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20355320.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Resorcinols; 0 / Salicylates; 11XLA0494B / orsellinic acid; 480-56-8 / lecanoric acid
  •  go-up   go-down


35. Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol; 2001 May;2(5):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
  • Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patients with advanced-stage head and neck cancer.
  • Here we review the results of both induction chemotherapy and chemoradiotherapy trials in patients with curable disease, and chemotherapy trials in patients with recurrent and metastatic disease, and we highlight current areas of investigation.
  • Compared with traditional treatment modalities, chemotherapy given on induction schedules to patients with advanced laryngeal cancer allows greater organ preservation without compromise to survival; when given concomitantly with radiotherapy to patients with resectable or unresectable advanced disease, chemotherapy again improves survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy, Combination. Humans. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Randomized Controlled Trials as Topic. Research. Survival Rate


36. Relic A, Scheich M, Stapf J, Voelter C, Hoppe F, Hagen R, Pfreundner L: Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol; 2009 Nov;266(11):1799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.
  • Induction chemotherapy followed by primary radiotherapy in responders is considered an alternative to surgery for advanced cancer of the larynx and hypopharynx (LHC).
  • Comparison of therapeutic approaches is challenging and must respect oncological and functional outcome as well as quality of life during and after treatment.
  • One aspect of primary radiochemotherapy is the option of salvage surgery in case of residual tumor.
  • All patients undergoing induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy from 01/96 to 07/05 were included.
  • Complete tumor removal, perioperative morbidity, and overall survival were analyzed in a retrospective study.
  • 28 out of 134 patients underwent salvage surgery after primary treatment with induction chemotherapy and radiotherapy for advanced LHC.
  • 15 patients had laryngectomy (LE) with neck dissection (ND), while 1 patient had lasersurgical partial laryngeal resection with ND for local recurrences.
  • In 56% of the cases, tumor removal turned out to be microscopically incomplete.
  • Eight out of 12 patients who underwent salvage ND because of suspicious lymph nodes (66%) were free of vital tumor.
  • When metastatic disease was present in the neck (4/12), recurrences occurred in 75% during postoperative follow-up.
  • Only 2 out of 20 patients undergoing surgery for histologically proven recurrence after radiochemotherapy (10%) are actually tumor-free and alive after a mean observation time of 43.9 months.
  • ND for suspicious persistent nodal disease after radiochemotherapy can be an over-treatment.
  • In the light of our results, unfavourable outcome after salvage surgery must be pointed out when initially informing patients about different therapeutic options for advanced LHC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Taxoids / therapeutic use. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 Aug;102(8):934-9 [1495357.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Sep;95(2):213-8 [3108762.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5 [9708712.001]
  • [Cites] Strahlenther Onkol. 2002 Jul;178(7):363-8 [12163990.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31 [16702569.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5 [7840923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1473-7 [11115285.001]
  • [Cites] Head Neck. 2007 Aug;29(8):715-9 [17274056.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] Am J Otolaryngol. 2005 Nov-Dec;26(6):388-92 [16275407.001]
  • [Cites] Head Neck. 2002 Aug;24(8):759-65 [12203801.001]
  • [Cites] Acta Otolaryngol. 2005 Jan;125(1):91-5 [15799582.001]
  • [Cites] J Laryngol Otol. 1993 Feb;107(2):130-2 [8496645.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1297-301 [7037159.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):662-4 [8988672.001]
  • [Cites] Acta Oncol. 2002;41(1):69-76 [11990522.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):441-8 [17180512.001]
  • [Cites] J Laryngol Otol. 1972 Aug;86(8):785-93 [5044285.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):673-8 [3338032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Laryngoscope. 1980 Jun;90(6 Pt 1):930-45 [7382709.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):855-8 [16735902.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):892-8 [10828805.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(11):1225-8 [17050318.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jul;131(1):61-8 [15243559.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Dec;104(12):936-41 [7492064.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1887-93 [2414254.001]
  • [Cites] Cancer. 1982 Dec 15;50(12 ):2795-801 [6182982.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1864-6 [17003711.001]
  • [Cites] J Laryngol Otol. 1984 Sep;98(9):905-7 [6481227.001]
  • [Cites] Head Neck. 1997 Mar;19(2):116-20 [9059868.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):350-6 [2759253.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Apr;112(4):437-9 [3484960.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):245-9 [2325423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1975 Nov-Dec;84(6):833-40 [1053455.001]
  • [Cites] Head Neck. 2005 Aug;27(8):653-8 [16035097.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Jun;115(6):419-24 [16805372.001]
  • [Cites] Radiother Oncol. 1984 Jun;2(1):31-6 [6505273.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):97-101 [7837923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):420-4 [9109791.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2000 Apr;25(2):146-52 [10816221.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Head Neck. 2005 Feb;27(2):101-7 [15529321.001]
  • (PMID = 19288123.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


37. Palencár D, Hedera J, Fedeles J, Dolezal J, Pind'ák D: Reconstruction of a circular defect of the hypopharynx and cervical part of esophagus by a free jejunal flap (case report). Acta Chir Plast; 2005;47(2):35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of a circular defect of the hypopharynx and cervical part of esophagus by a free jejunal flap (case report).
  • Reconstruction of the hypopharynx and esophagus is desirable in cases of congenital deformities, corrosive injuries, or defects after tumor resections.
  • In this article, the authors present a case of complete hypopharynx closure in an oncology patient with a larynx carcinoma.
  • The patient is a 60-year-old male diagnosed in 2002 with epidermoid carcinoma of larynx.
  • The patient underwent laser resection of the tumor followed by radiotherapy and chemotherapy.
  • In 2003 the patient underwent pharyngo - laryngectomy for relapse of the larynx carcinoma.
  • Postoperatively the patient developed pharyngo - cutaneous fistula, which was reconstructed at the otorhinolaryngology department by a muscle - cutaneous flap from the pectoralis major muscle.
  • During the course of healing the patient developed complete hypopharynx and cervical esophagus closure.
  • On the second day after the surgery patient developed salivary fistula in the wound.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharynx / surgery. Jejunum / transplantation. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Humans. Laser Therapy. Male. Postoperative Complications. Reconstructive Surgical Procedures. Salivary Gland Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035154.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


38. Vachin F, Hans S, Atlan D, Brasnu D, Menard M, Laccourreye O: [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy]. Ann Otolaryngol Chir Cervicofac; 2004 Jun;121(3):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results of exclusive chemotherapy for glottic squamous cell carcinoma complete clinical responders after induction chemotherapy].
  • [Transliterated title] Résultats à long-terme de la chimiothérapie exclusive des cancers épidermoïdes glottiques.
  • OBJECTIVES: To evaluate the long-term results of exclusive chemotherapy for T1-T3N0M0 glottic squamous cell carcinoma complete clinical responders after induction chemotherapy.
  • MATERIAL AND METHODS: Between 1985 and 2000, 69 patients with glottic squamous cell carcinoma complete clinical responders after induction chemotherapy were managed with exclusive chemotherapy at our department.
  • Chemotherapy associated platinum and fluorouracil.
  • This retrospective analysis evaluated actuarial survival, treatment morbidity, oncologic events and laryngeal preservation.
  • RESULTS: The 5-year Kaplan-Meier actuarial survival, local control, lymph node control estimate were 83,6%, 64,8%, 98,6% respectively.
  • Chemotherapy never resulted in death.
  • The 10-year actuarial metachronous second primary tumors estimate was 32%.
  • The overall laryngeal preservation rate was 98,6%.
  • CONCLUSION: Altogether our data and the review of the literature suggest that in patients achieving a complete clinical response after and induction based chemotherapy regimen, the completion of an exclusive chemotherapy regimen appears to be a valid alternative to the conventional use of radiotherapy or chemo-radiation protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15223999.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


39. Haigentz M Jr, Silver CE, Hartl DM, Takes RP, Rodrigo JP, Robbins KT, Rinaldo A, Ferlito A: Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother; 2010 Jun;11(8):1305-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy regimens and treatment protocols for laryngeal cancer.
  • IMPORTANCE OF THE FIELD: Laryngeal cancer has been the model of curative-intent organ-preserving therapies in clinical oncology.
  • Although the optimal care of patients with laryngeal cancer is truly multidisciplinary, with progressive advances in surgical, radiation, and medical oncology, the development of effective systemic therapies has been a major component of the therapeutic arsenal against laryngeal cancer.
  • AREAS COVERED IN THIS REVIEW: This review will discuss the rapidly evolving roles of chemotherapy in the management of locally advanced and metastatic laryngeal cancer.
  • WHAT THE READER WILL GAIN: The reader will gain a historical perspective on this evolution in treatment and will appreciate current treatment challenges and promising future directions in optimizing therapeutic efficacy in functional larynx preservation and in patient survival.
  • TAKE HOME MESSAGE: The treatment of most patients with laryngeal cancer with systemic therapy represents an opportunity to positively impact functional outcomes with an anatomically and functionally preserved larynx.
  • Future challenges include identification of novel therapies and optimizing therapy protocols for individualized patient care.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Interdisciplinary Communication. Medical Oncology. Pathology, Molecular. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429666.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  •  go-up   go-down


40. Varghese BT, Sebastian P, Mathew A: Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol; 2009 Dec;129(12):1480-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study.
  • CONCLUSIONS: Compared with larynx cancers salvage rates are poorer for hypopharyngeal cancers and the role of primary surgery seems to be significantly higher and more decisive in overall survival (OS).
  • OBJECTIVE: To evaluate the survival and morbidity of patients treated by surgery for carcinoma of the larynx and hypopharynx according to site.
  • PATIENTS AND METHODS: All patients who had undergone laryngectomy at the Division of Surgical Oncology Regional Cancer Center (RCC) from June 1995 to December 2005 were included in the study, which retrospectively recorded the age and sex distribution, TNM stage, indication, type of laryngectomy and reconstructive option used.
  • The therapeutic outcome, disease-free survival (DFS), OS, voice preservation and postoperative voice rehabilitation were analysed.
  • RESULTS: Of a total of 167 cases, 123 (74%) had salvage surgery for failed chemoradiotherapy/radical radiotherapy and 44 (26%) had primary surgical treatment.
  • Five patients received platinum-based neoadjuvant chemotherapy and nine had postoperative chemotherapy.
  • There was a statistically significant survival difference between salvage and primary surgical cases among cancers of the larynx and hypopharynx.
  • One patient refused further surgical closure after a partially failed repair.
  • Fifty-six (34%) patients recurred locoregionally, 4 (2.3%) patients developed a second primary and 5 (2.9%) had distant metastasis.
  • Thirty patients were voice rehabilitated with an electronic larynx.
  • Seventeen patients had voice prosthesis insertion (6 primary and 10 secondary), 3 patients developed good oesophageal speech and voice preservation was possible in 18 patients.
  • Seventy-nine patients were alive at the time of completing the study.
  • [MeSH-major] Carcinoma / surgery. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922101.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Gagnon PJ, Galderisi C, Page BR, Holland JM: Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx. Head Neck; 2009 Jun;31(6):829-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
  • BACKGROUND: Angiosarcoma arising after radiation is described in breast cancer but occurs elsewhere.
  • METHODS: This is a case of angiosarcoma developing 5 years after curative therapy for T3N0 squamous cell carcinoma of the supraglottic larynx.
  • Therapy consisted of 3 cycles of induction cisplatin/5-fluorouracil chemotherapy followed by radiotherapy.
  • Examination showed a 7-cm mass and biopsy revealed angiosarcoma.
  • CT scans assessed the local extent of the tumor and ruled out metastatic disease prior to initiating therapy.
  • RESULTS: Therapy consisted of 4 cycles of paclitaxel chemotherapy.
  • At completion, examination revealed mild induration of the neck with near-complete resolution of the mass.
  • CONCLUSION: This rare therapy-related second malignancy developed after curative larynx-preserving treatment.
  • Paclitaxel was an effective therapy in this setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Hemangiosarcoma / etiology. Laryngeal Neoplasms / therapy. Radiotherapy, High-Energy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18853452.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


42. Kawecki A, Jagielska B, Falkowski S: [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results]. Otolaryngol Pol; 2000;54 Suppl 31:21-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results].
  • In the Head and Neck Cancer Department of Cancer Centre in Warsaw between 1994 and 1998 fifty three patients with recurrent or metastatic laryngeal cancer were treated with methotrexate-based chemotherapy.
  • Chemotherapy protocol consist of methotrexate, vinblastine, 5-fluorouracil, bleomycin, cyclophosphamide and steroids used every two weeks.
  • Before treatment, unresectable local recurrence was observed in 35 patient and distant secondaries in 18 others.
  • Tolerance of treatment was acceptable.
  • Partial regression of the tumor was obtained in 30% of patients.
  • Presented program is an effective alternative to supportive treatment in patients with recurrent or metastatic laryngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974834.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


43. Sriussadaporn S, Pak-art R, Sriussadaporn S: Small-diameter H-graft portacaval shunt for variceal hemorrhage: experience at King Chulalongkorn Memorial Hospital. J Med Assoc Thai; 2004 Apr;87(4):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Portosystemic shunts remain to be a good means for preventing recurrent variceal hemorrhage in a certain number of patients who fail to respond to other therapeutic modalities.
  • Distal splenorenal shunt is too technically demanding.
  • PTFE graft has been performed to prevent recurrent variceal hemorrhage in cirrhotic patients who failed to respond to long term pharmacotherapy and endoscopic therapy during the last 3 years at our institution.
  • Data analysis included: causes of cirrhosis, patients' Child-Pugh classification, operative time, operative blood transfusion, and results of treatment.
  • The operative time ranged from 225 to 420 minutes (mean 303, median 285 minutes).
  • One patient developed hepatic encephalopathy at 35 months postoperation which was thought to be secondary from progression of the hepatic parenchymal disease.
  • One patient developed recurrent variceal hemorrhage at 30 months postoperation from portal vein thrombosis and was successfully treated by endoscopic variceal sclerotherapy (EVS).
  • One patient died from carcinoma of the larynx 3 months after SDHGPCS and 2 died from end stage liver disease at 30 and 45 months after SDHGPCS.
  • The procedure is simple and practical to perform in hospitals with low volume of portosystemic shunt operations.
  • The authors recommended SDHGPCS as an alternative in prevention of recurrent variceal hemorrhage in cirrhotic patients who fail to respond to other therapeutic modalities.
  • [MeSH-major] Esophageal and Gastric Varices / surgery. Gastrointestinal Hemorrhage / surgery. Portacaval Shunt, Surgical
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Thailand

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217183.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


44. Ferlito A, Silver CE, Rinaldo A, Smith RV: Surgical treatment of the neck in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec; 2000 Jul-Aug;62(4):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of the neck in cancer of the larynx.
  • Current concepts in management of the clinically negative and clinically positive neck in laryngeal cancer are reviewed.
  • Immunohistochemistry or molecular analysis may detect metastatic involvement not apparent by light microscopy.
  • The surgeon should be aware of the relatively high incidence of micrometastases in patients with laryngeal cancer to establish optimal treatment approaches.
  • Elective treatment of the neck is recommended for supraglottic tumors staged T2 or higher, and glottic or subglottic tumors staged T3 or higher.
  • The neck may be treated electively by either surgery or irradiation, but irradiation is best reserved for cases where that modality is employed for the primary tumor.
  • Elective neck dissection provides important information for prognostic purposes and therapeutic decisions, by establishing the presence, number, location and nature of occult lymph node metastases.
  • The selective lateral neck dissection (levels II, III and IV), unilateral or bilateral, is the procedure of choice for elective treatment.
  • Paratracheal nodes (level VI) should be dissected in cases of advanced glottic and subglottic cancer.
  • Sentinel lymph node biopsy may fail to detect tumor on frozen section examination or may not reveal 'skip' metastases.
  • More advanced disease has been treated in this manner often in association with adjuvant chemotherapy and/or irradiation.
  • While the benefit of adjuvant treatment is difficult to assess, it appears most useful in cases with extranodal spread of disease, a factor associated with the worst prognosis.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Lymph Node Excision. Neck / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10859523.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 114
  •  go-up   go-down


45. Erisen LM, Coskun H, Ozuysal S, Basut O, Onart S, Hizalan I, Tezel I: Basaloid squamous cell carcinoma of the larynx: a report of four new cases. Laryngoscope; 2004 Jul;114(7):1179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the larynx: a report of four new cases.
  • OBJECTIVES: This study is designed to report the clinical and pathologic features and outcome of cases of basaloid squamous cell carcinoma (BSCC) of the larynx treated in our clinic.
  • METHODS: Four cases of BSCC of the larynx were treated in our department.
  • Histopathologic slides were reevaluated to confirm the diagnosis.
  • RESULTS: All patients were male (mean 57), with supraglottic or transglottic larynx tumors.
  • Initial diagnosis was invasive squamous cell carcinoma in 3 patients and BSCC in one patient.
  • Three patients received adjuvant postoperative radiotherapy, and 2 of them also received additional chemotherapy.
  • Patients with stage-IV disease were found to have 4 and 27 metastatic lymph nodes on histopathologic examination and died because of distant metastases at 11 and 14 months, respectively.
  • CONCLUSION: In contrast with the literature reporting the tendency of more aggressive clinical behavior of the BSCC, we can say that BSCC has a behavior similar to conventional squamous cell carcinoma based on our 4 cases.
  • [MeSH-major] Carcinoma, Basosquamous / therapy. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neck Dissection. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15235344.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Klune JR, Zuckerbraun B, Tsung A: Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report. Int Semin Surg Oncol; 2010;7(1):1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report.
  • We report here on a patient that had been previously treated for squamous cell laryngeal cancer with surgical resection and adjuvant systemic chemotherapy that presented with a metastasis to the rectus abdominis muscle without evidence of recurrent disease at the primary site.
  • After a metastatic workup with PET/CT scan suggested this to be an isolated lesion, surgical excision with negative margins was performed based upon limited treatment options secondary to the location of the tumor and his favorable prognosis suggested by his pathological staging at the time of the initial resection.
  • Here we discuss the incidence of distant metastases from laryngeal cancer and appropriate screening methods.
  • Additionally, skeletal muscle metastases and treatment considerations are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):397-401 [10718426.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Dec;11(6):375-8 [11822863.001]
  • [Cites] J Laryngol Otol. 2003 Jan;117(1):85-7 [12590867.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):412-21; discussion 421-2 [14501507.001]
  • [Cites] Endoscopy. 2004 May;36(5):472 [15100974.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Sep;131(3):321-3 [15365554.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):377-80 [15886946.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):708-11; quiz 752, 753 [16246684.001]
  • [Cites] J Laryngol Otol. 2005 Oct;119(10):784-90 [16259655.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):242-4 [16487102.001]
  • [Cites] Top Magn Reson Imaging. 2007 Jun;18(3):193-202 [17762383.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):401-3 [19235784.001]
  • [Cites] Head Neck. 1997 Sep;19(6):500-5 [9278758.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1361-5 [9788864.001]
  • [Cites] Head Neck. 2000 Oct;22(7):680-6 [11002323.001]
  • (PMID = 20187979.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2838919
  •  go-up   go-down


47. Lu S, Xu W, Fan Z, Liu W, Li J, Wang H: Overexpression of Smac/DIABLO in Hep-2 cell line: possible role in potentiating the sensitivity of chemotherapeutic drugs. Tumori; 2010 Mar-Apr;96(2):310-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Smac/DIABLO in Hep-2 cell line: possible role in potentiating the sensitivity of chemotherapeutic drugs.
  • AIMS AND BACKGROUND: The major obstacles for tumor chemotherapy are drug resistance and/or adverse effects on the host.
  • In the present study we investigated the role of the second mitochondria-derived activator of caspase (Smac/DIABLO) in the action of cisplatin (DDP), 5-fluorouracil (5-FU), and the combination of both in Hep-2 cells.
  • METHODS AND STUDY DESIGN: Hep-2 laryngeal carcinoma cells exposed to DDP, 5-FU and the combination of both were investigated.
  • Cell viability was determined by MTT assay.
  • RESULTS: DDP, 5-FU and the combination of both drugs reduced the cell survival rates in a concentration- and time-dependent manner.
  • The drug combination not only exerted a stronger inhibitory effect, but also at a lower concentration compared with the single drugs.
  • The expression of Smac/DIABLO increased significantly at both mRNA and protein levels after cell exposure to the combination compared with single drugs.
  • CONCLUSIONS: Smac/DIABLO plays a pivotal role in attaining a synergistic effect in Hep-2 cells in response to this combined strategy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / physiology. Laryngeal Neoplasms / drug therapy. Mitochondrial Proteins / physiology
  • [MeSH-minor] Caspase 3 / analysis. Caspase 9 / analysis. Cell Line, Tumor. Cell Survival / drug effects. Cisplatin / pharmacology. Flow Cytometry. Fluorouracil / pharmacology. Humans. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572591.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Avcu S, Izmirli M, Nursun Ozcan H, Sengül I, Lemmerling M: Aryepiglottic fold and subcutaneous metastases from breast carcinoma. JBR-BTR; 2009 Nov-Dec;92(6):283-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aryepiglottic fold and subcutaneous metastases from breast carcinoma.
  • We report the CT findings in a 77-year-old woman with left-sided aryepiglottic fold metastasis from breast cancer diagnosed 7 years previously.
  • Biopsy of the lesion revealed metastasis from poorly differentiated adenocarcinoma, compatible with metastasis of the breast carcinoma.
  • Before detection of the laryngeal lesion, a second primary tumor in the right ovary was diagnosed.
  • After right oopherectomy, histopathology revealed clear cell adenocarcinoma.
  • Chemotherapy was applied to the patient.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Laryngeal Neoplasms / secondary. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Aged. Contrast Media. Epiglottis / pathology. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20166496.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


49. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM: Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res; 2004 Sep 1;10(17):5930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
  • PURPOSE: Epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (Cox-2) contribute to development of squamous cell carcinoma of the head and neck (SCCHN).
  • Simultaneously blocking both EGFR and Cox-2-mediated pathways may be an efficient means of inhibiting cancer cell growth in SCCHN.
  • EXPERIMENTAL DESIGN: A combination of EGFR-selective tyrosine kinase inhibitors (TKIs) AG1478 or ZD1839 (Iressa or gefitinib) with a Cox-2 inhibitor (Cox-2I) celecoxib (Celebrex) was studied for its effects on cell growth, cell cycle progression, and apoptosis in SCCHN cell lines by cell growth assay, clonogenic assay, flow cytometric analysis, and terminal deoxynucleotidyl transferase-mediated nick end labeling assay.
  • Primary and secondary targets of EGFR TKIs and Cox-2I were also examined using immunoblotting and immunoprecipitation after the combined treatment.
  • RESULTS: The combination of AG1478 or ZD1839 with celecoxib either additively or synergistically inhibited growth of the five SCCHN cell lines examined, significantly induced G(1) arrest and apoptosis, and suppressed capillary formation of endothelium.
  • Furthermore, the combination showed strong reductions of p-EGFR, p-extracellular signal-regulated kinase 1/2, and p-Akt in SCCHN cells as compared with the single agents.
  • CONCLUSIONS: These results suggest that cell growth inhibition induced by a combination of EGFR TKIs and Cox-2I is mediated through simultaneously blocking EGFR and Cox-2 pathways.
  • This combination holds a great potential for the treatment and/or prevention of SCCHN.
  • [MeSH-major] Apoptosis / drug effects. Enzyme Inhibitors / pharmacology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / enzymology. Isoenzymes / antagonists & inhibitors. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Celecoxib. Cell Cycle / drug effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / pharmacology. Drug Synergism. Drug Therapy, Combination. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Flow Cytometry. Humans. Immunoblotting. Immunoprecipitation. In Situ Nick-End Labeling. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / enzymology. Lymphatic Metastasis / pathology. Membrane Proteins. Neovascularization, Pathologic. Prostaglandin-Endoperoxide Synthases. Pyrazoles / pharmacology. Quinazolines / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured. Tumor Stem Cell Assay. Tyrphostins / pharmacology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15355926.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA101244
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; 0 / Tyrphostins; 170449-18-0 / tyrphostin AG 1478; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib
  •  go-up   go-down


50. Jia SS, Wang YY, Pei R, Sun J: [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Feb;40(2):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma].
  • OBJECTIVE: To study the pathologic feature and management methods of occult lymphatic metastasis in patients with supraglottic carcinoma.
  • (1) Supraglottic squamous cell carcinoma;.
  • (3) no preoperative radiotherapy and (or) chemotherapy.
  • The distribution of metastatic lymph nodes was 9 in level II, 1 in level III, no in level I.
  • N0 recurrence in larynx and (or) at the neck after dissection.
  • Two years survival rates was 86.7% (26/30) without tumor.
  • CONCLUSION: Occult metastasis rate of supraglottic carcinoma is as high as 30%.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Laryngeal Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429726.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


51. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K: Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther; 2003 Jan;10(1):51-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice.
  • The application of adeno-associated virus (AAV) vectors to cancers is limited by their low transduction efficiency.
  • Previously, we reported that gamma-ray enhanced the second-strand synthesis, leading to the improvement of the transgene expression, and cytocidal effect of the herpes simplex virus type-1 thymidine kinase (HSVtk) and ganciclovir (GCV) system.
  • First, the laryngeal cancer cell line (HEp-2) and HeLa were treated with AAVtk/GCV, the number of surviving cells was reduced as the concentration of GCV increased.
  • Furthermore, the 4 Gy irradiation enhanced the killing effects of AAVtk/GCV by four-fold on HeLa cells and 15-fold on HEp-2 cells.
  • These findings suggest that the combination of AAVtk/GCV system with radiotherapy is significantly effective in the treatment of cancers and may lead to reduction of the potential toxicity of both AAVtk/GCV and gamma-ray.
  • [MeSH-major] Antiviral Agents / administration & dosage. Ganciclovir / administration & dosage. Genetic Therapy / methods. Genetic Vectors / administration & dosage. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / therapy. Transduction, Genetic / methods
  • [MeSH-minor] Animals. Combined Modality Therapy. Dependovirus / genetics. Dose-Response Relationship, Drug. Gene Expression / radiation effects. HeLa Cells. Humans. Mice. Mice, Nude. Radiotherapy Dosage. Simplexvirus / enzymology. Thymidine Kinase / genetics. Transplantation, Heterologous. Tumor Cells, Cultured. beta-Galactosidase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525837.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; EC 3.2.1.23 / beta-Galactosidase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


52. Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R: Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer; 2010 Oct;18(10):1263-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
  • BACKGROUND/PURPOSE: Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer.
  • METHODS: In this open-label pilot feasibility trial, patients with no prior chemotherapy for metastatic colorectal cancer were included.
  • Treatment consisted of capecitabine 1,000 mg/m(2) bid on days 1-14 and oxaliplatin 130 mg/m2 on day 1 of a 21-day cycle.
  • The primary endpoint was feasibility and drug reactions during the infusion.
  • Secondary endpoints included acute and chronic neuropathy as well as response rate.
  • Apart from one patient with laryngeal spasm, no other infusion-related adverse events were observed.
  • Of the patients, 35% reported grade 3/4 acute dysesthesia or paresthesia according to a patients questionnaire.
  • While we have observed a relatively low rate of chronic cumulative neuropathy with heated oxaliplatin, this procedure appears not promising enough for us to recommend its further clinical evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Hot Temperature. Neurotoxicity Syndromes / prevention & control
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Pilot Projects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13 [14523789.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33 [12422305.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):4028-9 [17664456.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61 [15217938.001]
  • [Cites] J Peripher Nerv Syst. 2006 Jun;11(2):135-41 [16787511.001]
  • [Cites] Support Care Cancer. 2006 Mar;14(3):223-9 [16021477.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90 [18309961.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Oncologist. 2007 Mar;12(3):312-9 [17405895.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1288-92 [18349029.001]
  • [Cites] Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46 [15871765.001]
  • [Cites] Qual Life Res. 1997 Apr;6(3):225-36 [9226980.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] Support Care Cancer. 2006 May;14(5):484-7 [16450089.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17 [7932825.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] BMC Cancer. 2005 Sep 16;5:116 [16168057.001]
  • [Cites] Ann Oncol. 2004 May;15(5):781-5 [15111347.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1666-72 [17660495.001]
  • (PMID = 19756772.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Gallegos-Hernández JF: Partial surgery of the larynx: techniques and outcomes. Cir Cir; 2010 Sep-Oct;78(5):451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial surgery of the larynx: techniques and outcomes.
  • BACKGROUND: in recent years preservation of the larynx has been one of the most studied subjects in the field of cervicofacial oncology and is the secondary target in the treatment of laryngeal cancer after locoregional control.
  • DISCUSSION: Treatment of cancers originating generally in the mucosa of the head and neck and in particular of the larynx has evolved greatly during the past 10 years.
  • Inclusion of induction chemotherapy and the association of concomitant chemotherapy/radiotherapy in the medical armamentarium has totally changed the therapeutic strategy for this neoplasm.
  • These techniques allow extirpation of the neoplastic portion of the organ, obtaining oncological treatment but preserving voice function, understandable phonation, normal swallowing function and breathing without tracheotomy.
  • It is important to determine whether these techniques are still useful in the present context of multidisciplinary treatment of laryngeal cancer.
  • The objective of this study is to demonstrate techniques, indications and errors to avoid in three surgical techniques considered useful to treat endolaryngeal tumors, preserving function.
  • CONCLUSIONS: in neoplasms of the larynx, in early as well as intermediate stages, these techniques offer excellent voice quality and suitable control specific to tumors located within the larynx.
  • In these patients, partial surgery offers adequate oncological control and a safe therapeutic and functional alternative.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laryngectomy / methods
  • [MeSH-minor] Humans. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21219819.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


54. Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J: Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):582-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
  • OBJECTIVE: To evaluate the incidence and costs of complications due to radiotherapy alone vs platinum-based chemoradiotherapy among patients diagnosed as having advanced squamous cell carcinoma of the head and neck (ASCCHN) from a payer perspective.
  • PATIENTS: The study included patients with ASCCHN and an indication of a secondary malignant neoplasm (both identified based on International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis codes), 124 of whom were treated with radiotherapy alone and 77 of whom were treated with chemoradiotherapy (including 53 with cisplatin plus radiotherapy, 26 with carboplatin plus radiotherapy, and 2 with cisplatin and carboplatin plus radiotherapy).
  • The patients were assigned to 1 of 2 cohorts based on treatment type-radiotherapy only and platinum-based chemoradiotherapy-and were followed up for 6 months.
  • MAIN OUTCOME MEASURES: Incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN.
  • RESULTS: We found significantly (P < .001) higher rates of treatment-related complications among patients receiving chemoradiotherapy (86%) than among patients receiving only radiotherapy (51%).
  • The mean per-patient costs associated with treatment-related complications were approximately $10 000 higher among patients who received chemoradiotherapy than among those treated with radiotherapy alone (P < .001).
  • CONCLUSIONS: Our study results suggest that the attributable incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN are substantial.
  • The emergence of safer treatments may have the advantage of alleviating this cost burden.
  • [MeSH-major] Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / therapy. Cost of Illness. Head and Neck Neoplasms / economics. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carboplatin / adverse effects. Cisplatin / adverse effects. Combined Modality Therapy. Databases, Factual. Drug Therapy / economics. Drug-Related Side Effects and Adverse Reactions. Female. Hospitalization. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / economics. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / economics. Pharyngeal Neoplasms / radiotherapy. Postoperative Complications / economics. Radiation-Sensitizing Agents / adverse effects. Radiotherapy / adverse effects. Radiotherapy / economics. Retrospective Studies. Tongue Neoplasms / drug therapy. Tongue Neoplasms / economics. Tongue Neoplasms / radiotherapy. United States

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528407.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


55. Lesinski-Schiedat A, Hemmanouil I, Sauer-Gönen M, Flemming P, Freihorst I, Kempf HG, Lenarz T: [Malignant transformation of a juvenile papilloma in a 11 year old boy]. Laryngorhinootologie; 2005 Aug;84(8):602-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of a juvenile papilloma in a 11 year old boy].
  • BACKGROUND: The juvenile laryngeal papilloma is the most common benign neoplasm in children.
  • Sporadic malignant transformation in adults with a papilloma was reported after treatment with radiotherapy alone or in combination with the intake of additional toxins (e. g. nicotine).
  • Similar reports of a malignant transformation of juvenile papillomas without additional risk factors is very rarely reported.
  • CASE REPORT: We report about an 11 year old boy, who suffered from a juvenile laryngeal papilloma.
  • The multiple laser surgical procedures and a therapy with interferon resulted in a short-term remissions.
  • Seven months after the first diagnosis of the papilloma a regional metastatic squamous cell carcinoma was found.
  • In spite of combined radiotherapy and chemotherapy the boy died 11 months later.
  • CONCLUSIONS: The spontaneous malignant transformation of a juvenile papilloma in a squamous cell carcinoma is extremely rare.
  • The surgical intervention as well the radiotherapy and chemotherapy using interferon was unsuccessful due to the high grade of malignancy.
  • In view of the very short time interval between first diagnosis of juvenile papilloma and the subsequent malignant transformation, one must consider either the potential presence of a very aggressive form of papilloma or alternative two coincident independent diseases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Laryngeal Neoplasms / pathology. Papilloma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080063.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


56. Oboón B, Zalba B, López C, Gutiérrez I, Villanueva B, González J: [Exoftalmos and palpebral ptosis in the immunocompromised patient]. An Med Interna; 2003 Jun;20(6):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Exoftalmos y ptosis palpebral en paciente inmunodeprimido.
  • The mucormycosis is an opportunistic mycosis which has a high rate of global mortality with a bad prognosis.
  • The present clinical case shows a patient attended in the Intensive Care Unit because of a breathing insufficiency secondary to a pneumonia.
  • Among his antecedents there is a larynx carcinoma totally remittent after chemo- and radiotherapy.
  • Having that evolution, it is implemented a treatment with liposomal amphotericin B and granulocyte colony-stimulating factors after an injury biopsy, whose posterior cultive shows growing of Mucor.
  • This kind of pathology must be initially suspected in all the patients with a neoplasia and its treatment must be early and agressive.
  • At the moment the diagnosis is suspected there is a great tissue destruction and for that reason the patients usually die in spite of the instauration of aggressive therapies
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Fatal Outcome. Humans. Immunocompromised Host. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Male. Malnutrition / complications. Malnutrition / immunology

  • Genetic Alliance. consumer health - Ptosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12848603.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Bonfils P, Trotoux J, Bassot V: Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol; 2007 Feb;121(2):143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone in laryngeal squamous cell carcinoma.
  • AIMS: To evaluate the results of chemotherapy alone in patients with invasive squamous cell carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • METHODS: A comparison of results in a group of complete responders managed with a chemotherapy alone protocol, matched with those of an incomplete responder group managed with conventional modalities.
  • CONCLUSION: Our results confirm the fact that chemotherapy alone is a viable option in selected patients with carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • This therapeutic approach allows surgery and/or radiation therapy to be reserved for the management of metachronous second primary tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005065.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Valentí V, López-Pousa A, Gonzalez Y, Farré N: Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature. J Craniofac Surg; 2005 May;16(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature.
  • The case of a 56-year-old man with osteogenic sarcoma of the mandible diagnosed 7 years after radiotherapy treatment of a laryngeal cancer is reported.
  • Surgery was the initial treatment.
  • The progress was poor after local and pulmonary relapse, without response to chemotherapy treatment.
  • The authors have found in the literature 30 cases of mandibular radiation-induced osteogenic sarcomas, most of them secondary to treatment of benign lesions, none of them secondary to treatment of a laryngeal cancer, as was seen in their case.
  • [MeSH-minor] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / radiotherapy. Fatal Outcome. Humans. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915114.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Dilkes MG, Benjamin E, Ovaisi S, Banerjee AS: Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol; 2003 Sep;117(9):713-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases.
  • The use of photodynamic therapy for the treatment of malignant and non-malignant conditions is increasing.
  • This paper demonstrates the efficacy of a second-generation photosensitizer, Foscan, in the primary treatment of a wide range of mucosal head and neck squamous cell carcinomas.
  • Tumours ranged in stage from T(1) to T(3).
  • A complete response to primary treatment was seen in 19/21 patients (90 per cent).
  • In laryngeal cancer recurrent after radical radiotherapy, one out of four patients treated obtained a complete response (25 per cent).
  • Six patients (24 per cent) required surgery after photodynamic therapy, for local recurrence or dysplasia.
  • Mean follow up was for 27.3 months (standard deviation 20.6 months).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561360.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


60. Nur DA, Oguz C, Kemal ET, Ferhat E, Sülen S, Emel A, Münir K, Ann CS, Mehmet S: Prognostic factors in early glottic carcinoma implications for treatment. Tumori; 2005 Mar-Apr;91(2):182-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in early glottic carcinoma implications for treatment.
  • AIM: In this study we aimed to determine the prognostic factors affecting local control (LC) in limited glottic carcinoma treated with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Between June 1991 and December 2001, 114 patients with early squamous-cell carcinoma of the glottis were treated with definitive RT at our institution.
  • A median dose of 66 Gy (50-70.2) was given over a median period of 46 days (20-60).
  • The prognostic parameters analyzed for LC were T classification, anterior commissure involvement, total RT dose, and overall treatment time.
  • RESULTS: Five-year local and regional control rates were 84.2% and 97.7%.
  • In 15 patients with local failure, salvage treatment consisted of partial laryngectomy in eight patients and total laryngectomy in five.
  • In one of the three patients with regional failure, salvage surgery was applied and the other two were given palliative chemotherapy because of unresectable disease.
  • Following salvage treatments, the ultimate five-year LC rate was 96.9% and the five-year larynx preservation rate was 91.1%.
  • Second primary cancer was diagnosed in 17 (14.9%) patients.
  • Only one patient developed distant metastases and two patients died of laryngeal cancer.
  • CONCLUSION: In patients with early glottic carcinoma, T classification proved to be the only independent prognostic factor affecting LC after primary radiotherapy according to the results of this study.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948549.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ansarin M, Planicka M, Rotundo S, Santoro L, Zurlo V, Maffini F, Alterio D, Cattaneo A, Chiesa F: Endoscopic carbon dioxide laser surgery for glottic cancer recurrence after radiotherapy: oncological results. Arch Otolaryngol Head Neck Surg; 2007 Dec;133(12):1193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic carbon dioxide laser surgery for glottic cancer recurrence after radiotherapy: oncological results.
  • OBJECTIVE: To evaluate local control, organ preservation, and complications after endoscopic laser surgery for early recurrent glottic cancer after radiotherapy.
  • PATIENTS: The study, which was conducted between May 1999 and September 2005, included 37 consecutive patients (33 men and 4 women) with recurrent glottic cancer after radiotherapy.
  • Selection criteria were as follows: rcTis, rcT1, or rcT2 with subglottic or supraglottic involvement of less than 5 mm and no arytenoid invasion; adequate laryngeal exposure; no previous open surgery; no contraindications to general anesthesia; and signed consent.
  • INTERVENTIONS: Endoscopic laser surgery with curative intent using types III to V cordectomies according to the European Laryngological Association.
  • MAIN OUTCOME MEASURES: Five-year actuarial recurrence-free and overall survival, complications, and rate of laryngeal preservation.
  • New recurrences developed in 13 patients (35%): 11 were treated by total laryngectomy, 1 by supracricoid laryngectomy, and 1 by chemotherapy.
  • Three patients died of laryngeal cancer, 1 is alive with disease, and 1 died of a second cancer.
  • The larynx was preserved in 26 patients (70%).
  • Laryngeal stenosis was the most common major complication (in 3 of 4 women and 1 of 33 men).
  • CONCLUSIONS: Endoscopic laser surgery is a safe and effective salvage procedure in selected cases involving glottic recurrence after radiotherapy.
  • Oncological results are satisfactory, and organ preservation can be achieved in a high proportion of cases; however, the risk of laryngeal stenosis is high in women.
  • [MeSH-major] Glottis. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngoscopy / methods. Laser Therapy / methods. Lasers, Gas. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086959.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. León X, López M, García J, Quer M: [Results of an organ conservation protocol in patients with locally advanced laryngeal tumours]. Acta Otorrinolaringol Esp; 2009 May-Jun;60(3):176-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of an organ conservation protocol in patients with locally advanced laryngeal tumours].
  • [Transliterated title] Resultados de un protocolo de preservación de órgano en pacientes con tumores localmente avanzados de la laringe.
  • INTRODUCTION AND OBJECTIVES: Advanced laryngeal carcinoma patients, candidates for total laryngectomy, nowadays have different treatment options.
  • One of them is induction chemotherapy, which allows modulation of the second manoeuvre according to the degree of response achieved.
  • This study presents the results of a large series of patients treated according to this protocol.
  • METHODS: Retrospective study of 370 patients with T3-T4 carcinomas of the larynx considered as candidates for total laryngectomy.
  • RESULTS: Seven patients died as a consequence of the treatment with chemotherapy.
  • Among 363 patients finishing chemotherapy, 154 (43 %) achieved complete response and proceeded with radiotherapy.
  • Total laryngectomy was performed in 135 (37 %) non-responders and 74 (20 %) patients were treated with radiotherapy in spite of an incomplete response to chemotherapy.
  • Larynx preservation was achieved in 42 % of the patients, rising to 72 % for complete responders to chemotherapy and to 62 % in non-responders receiving radiotherapy.
  • CONCLUSIONS: Our larynx preservation protocol including induction chemotherapy for patients with advanced carcinomas who are candidates for total laryngectomy achieved a total survival rate of 73 % with a 42 % larynx preservation rate.
  • The response to the induction chemotherapy was the factor contributing most to larynx preservation.
  • [MeSH-major] Laryngeal Neoplasms / therapy
  • [MeSH-minor] Aged. Clinical Protocols. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558903.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


63. Laccourreye O, Veivers D, Bassot V, Ménard M, Brasnu D, Laccourreye H: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Apr;111(4):315-21; discussion 321-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure.
  • Based on an inception cohort of 35 patients with T1-3N0M0 squamous cell carcinoma of the true vocal cord who had a complete clinical response after a platinum-based induction chemotherapy regimen and a minimum of 3 years of follow-up, the current retrospective study documented the long-term results and consequences of local recurrence following the use of a platinum-based chemotherapy-alone regimen for cure.
  • During the years 1985 to 1996, 231 patients with invasive squamous cell carcinoma of the true vocal cord classified as T1-3N0M0 were managed at our department with a platinum-based induction chemotherapy regimen.
  • Thirty-five of the 77 patients with complete clinical response were managed at our institution with a platinum-based chemotherapy-alone regimen.
  • The statistical analysis of data on survival, local control, nodal control, distant metastasis, and metachronous second primary tumor incidence was based on the Kaplan-Meier product limit method.
  • Overall, the causes of death were intercurrent disease in 6 patients and metachronous second primary tumor in 4 patients.
  • The 3- and 5-year actuarial local control estimate was 64.8%.
  • Salvage treatment in patients with local recurrence yielded a 100% local control rate and laryngeal preservation rate.
  • The 3- and 5-year actuarial lymph node control estimate was 97.1%.
  • The 5- and 10-year actuarial estimates for patients with metachronous second primary tumor were 9.7% and 28.1%, respectively.
  • Although local recurrence was noted in almost a third of patients with complete clinical response who were managed with a platinum-based chemotherapy-alone regimen, it did not appear to be detrimental, as none of the patients who had local recurrence ultimately died from their disease or lost their larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local. Vocal Cords
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chi-Square Distribution. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2002 Sep;111(9):860 [12296346.001]
  • (PMID = 11991582.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Cimbora-Zovko T, Ambriović-Ristov A, Loncarek J, Osmak M: Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance. Eur J Pharmacol; 2007 Mar 8;558(1-3):27-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance.
  • Acquired resistance to cisplatin represents a major obstacle to successful chemotherapy.
  • We have developed cisplatin-resistant CA3(ST) and CK2 cells, which exhibited altered formation of cell-cell junctions compared to their parental cisplatin-sensitive human laryngeal carcinoma HEp-2 cells.
  • Although cell-cell adhesion can induce antiapoptotic signaling, there is contradictory evidence considering the significance of cadherin-catenin complex in cellular response to cisplatin.
  • In both cisplatin-resistant sublines plakoglobin expression was decreased, while beta-catenin expression was increased, at cell-cell junctions.
  • Although cisplatin-resistant cells showed decreased plakoglobin mRNA, they retained equal expression of beta-catenin mRNA as parental cells.
  • Immunoprecipitation of cadherin-catenin complex established that upregulation of beta-catenin results from its stabilization through interaction with N-cadherin.
  • However, single cisplatin treatment of HEp-2 cells did not induce beta-catenin upregulation, nor plakoglobin mRNA downregulation, suggesting that the alteration in catenin ratio is a late event, which requires repeated cisplatin exposure.
  • Finally, we overexpressed plakoglobin in CA3(ST) cells and selected several clones that established the pattern of plakoglobin/beta-catenin expression found in HEp-2 cells.
  • Thus, it appears that beta-catenin and plakoglobin are not involved in the resistance development, implying that the observed alterations are an outcome of a slowly generating process, which is presumably a secondary event of vital cellular response triggered by cisplatin toxicity.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Adhesion / drug effects. Cisplatin / pharmacology. Desmoplakins / genetics. beta Catenin / genetics
  • [MeSH-minor] Cadherins / metabolism. Cell Line, Tumor. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / drug effects. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / metabolism. Laryngeal Neoplasms / pathology. RNA, Messenger / analysis. Transfection

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234182.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Desmoplakins; 0 / JUP protein, human; 0 / RNA, Messenger; 0 / beta Catenin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


65. Kanazawa T, Mizukami H, Nishino H, Okada T, Hanazono Y, Kume A, Kitamura K, Ichimura K, Ozawa K: Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells. Int J Oncol; 2004 Sep;25(3):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
  • Adeno-associated virus (AAV) is a non-pathogenic virus with a single-strand DNA genome.
  • AAV vectors have several unique properties suited for gene therapy applications.
  • However, an obstacle to their application is a low efficiency of transgene expression, mainly due to a limited second-strand synthesis.
  • Previously, we reported that gamma-rays enhanced the transduction efficiency and cytocidal effect of AAV vector harboring the herpes simplex virus-thymidine kinase (AAVtk) and ganciclovir (GCV) system.
  • The enhancement of transgene expression was observed in a concentration-dependent manner on human laryngeal carcinoma cells (HEp-2 cells) and HeLa cells.
  • Southern analysis confirmed that etoposide enhanced the double-strand synthesis of the AAV vector genome in HEp-2 cells and HeLa cells.
  • The cells were efficiently killed by AAVtk/GCV system, as expected.
  • These findings suggest that the combination of AAV-mediated suicide gene therapy and treatment with topoisomerase inhibitors may have synergistic therapeutic effects in the treatment of cancers.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Dependovirus / genetics. Ganciclovir / therapeutic use. Genes, Transgenic, Suicide. Head and Neck Neoplasms / therapy. Thymidine Kinase / genetics. Topoisomerase I Inhibitors
  • [MeSH-minor] Camptothecin / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / therapeutic use. Etoposide / pharmacology. Gene Expression. Genetic Therapy. Genetic Vectors / genetics. Humans

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15289876.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 6PLQ3CP4P3 / Etoposide; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


66. Marioni G, Blandamura S, Calgaro N, Ferraro SM, Stramare R, Staffieri A, De Filippis C: Distant muscular (gluteus maximus muscle) metastasis from laryngeal squamous cell carcinoma. Acta Otolaryngol; 2005 Jun;125(6):678-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant muscular (gluteus maximus muscle) metastasis from laryngeal squamous cell carcinoma.
  • Clinical evidence of non-lymphatic distant metastasis has been reported in approximately 10% of cases of head and neck squamous cell carcinoma (HNSCC).
  • A 65-year-old male underwent supraglottic laryngectomy and left modified neck dissection for a carcinoma of the laryngeal surface of the epiglottis extending to both false cords.
  • Eight months later the patient underwent right radical modified neck dissection for hypodermal metastatic disease involving the underlying (sternocleidomastoid) muscle.
  • Thirty-two months later, surgical excision of a lesion in the right gluteus maximus muscle was performed.
  • Histological study diagnosed a muscular metastasis with the same morphological aspect as the laryngeal carcinoma.
  • Although skeletal muscles represent approximately 50% of total body mass and receive a large proportion of total cardiac output, haematogenous metastases to skeletal muscle are extremely uncommon.
  • Treatment options, depending upon the clinical setting, include observation, radiotherapy, chemotherapy and excision; these approaches rarely alter the patient outcome.
  • [MeSH-major] Buttocks / pathology. Carcinoma, Squamous Cell / secondary. Laryngeal Neoplasms / pathology. Muscle Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076722.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


67. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The first is an 84-year-old male patient with cancer of the hypopharynx (T3N2aM1, stage IVc).
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


68. Dietz A, Nollert J, Eckel H, Volling P, Schröder M, Staar S, Conradt C, Helmke B, Dollner R, Müller RP, Wannenmacher M, Weidauer H, Rudat V: [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. HNO; 2002 Feb;50(2):146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study].
  • [Transliterated title] Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie. Ergebnisse einer multizentrischen Phase-II-Studie.
  • INTRODUCTION: Regarding the promising results of international trials we conducted the first German prospective multicentre phase II trial for organ preservation with primary simultaneous chemoradiation in advanced laryngeal and hypopharyngeal cancer.
  • PATIENTS AND METHODS: 28 of 30 recruited patients suffering from stage II and III (UICC) laryngeal and hypopharyngeal cancer were treated with primary simultaneous chemoradiation within an organ preservation program and monitored in follow-up of one year.
  • Exclusion criteria included tumor infiltration of the laryngeal cartilage, bilateral neck nodes (N2c) and need for flap reconstruction in case of laryngectomy.
  • The protocol included an accelerated concomitant boost chemoradiation (66 Gy) with Carboplatinum (70 mg/m2 1st and 5th week) and a restaging procedure one month after therapy.
  • RESULTS: After follow-up of one year 20 of 28 patients (71%) were presented with stable complete remission and functionally preserved larynx.
  • Of these 20 patients 3 developed pulmonary metastases, 1 secondary primary carcinoma of the lung and 3 neck metastases which needed neck dissections.
  • The other patients showed in 4 cases relapsing tumor which was indicated for laryngectomy.
  • One patient needed tracheotomy because of persisting edema and 2 patients died due to tumor progress.
  • Further studies should focus on the improvement of patient selection which could be realized by induction Chemotherapy (using new components like taxan) and/or use of prediction factors such as tumor volume and hemoglobin levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] HNO. 2002 Feb;50(2):109-13 [12080620.001]
  • (PMID = 12080625.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


69. Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet; 2000 Mar 18;355(9208):949-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.
  • BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain.
  • We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment.
  • We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx.
  • FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy.
  • There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy.
  • Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions.
  • Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy.
  • Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders.
  • The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46).
  • INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable.
  • For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / therapy. Proportional Hazards Models. Randomized Controlled Trials as Topic. Treatment Outcome


70. Genden EM, Ferlito A, Silver CE, Jacobson AS, Werner JA, Suárez C, Leemans CR, Bradley PJ, Rinaldo A: Evolution of the management of laryngeal cancer. Oral Oncol; 2007 May;43(5):431-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of the management of laryngeal cancer.
  • The treatment of laryngeal cancer has evolved through several phases, starting with wide extirpative surgical resection, and evolving through an era of conservation surgery and, finally, planned treatment using modalities of irradiation, chemotherapy and surgery in various combinations.
  • Attempts to extirpate laryngeal cancer date to the nineteenth century, but only by the mid-twentieth century did advances in anesthesia, blood transfusion and antibiotics, make this surgery safe and reliable.
  • Techniques of partial laryngectomy by external approach developed in the second half of the twentieth century, and endoscopic use of the laser refined the concept and provided a new paradigm for surgical treatment, particularly for early lesions.
  • During most of this era, radiation was employed as an alternative method of treatment, with surgery reserved for salvage of radiation failure.
  • By the last decade of the twentieth century, and to the present time, the value of combined modality therapy, using planned combinations of irradiation, chemotherapy and surgery became the standard of care for advanced laryngeal cancer, permitting maximal laryngeal preservation with the highest attainable cure rates.
  • [MeSH-major] Laryngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Otorhinolaryngologic Surgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112771.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


71. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R: TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther; 2002 Nov;9(11):951-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.
  • TNFerade Biologic (TNFerade) is a second-generation (E1-, E3-, and E4-deleted) replication-deficient adenovector carrying the transgene encoding for human tumor necrosis factor alpha (TNFalpha), regulated by the radiation-sensitive promoter Early Growth Response (Egr-1).
  • We hypothesized that intratumoral injection of TNFerade followed by radiation would result in potentially therapeutic levels of TNFalpha with minimal toxicity.
  • A total of 80 mice in the nude mouse toxicology study, all bearing human squamous cell carcinoma xenografts, 120 mice in the Balb/c study, and 33 nude mice in the pharmacokinetic study were used.
  • The pharmacokinetic study demonstrated high sustained levels of TNFalpha in the tumor homogenate with no "spillover" to plasma, where TNFalpha levels were below the level of detection.
  • In conclusion, a gene therapy approach with TNFerade, in combination with radiation, represents a potential way to utilize the potent anticancer activity of TNFalpha without systemic toxicity.
  • [MeSH-major] Gene Expression Regulation / radiation effects. Promoter Regions, Genetic / radiation effects. Tumor Necrosis Factor-alpha / therapeutic use. Tumor Necrosis Factor-alpha / toxicity
  • [MeSH-minor] Adenoviridae / genetics. Animals. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cell Survival / drug effects. Cell Survival / radiation effects. Genetic Therapy / methods. Humans. Laryngeal Neoplasms / immunology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Mice. Mice, Inbred BALB C. Mice, Nude. Sequence Deletion. Transfection / methods. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12386834.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


72. Burns P, Sheahan P, Doody J, Kinsella J: Clavicular osteomyelitis: a rare complication of head and neck cancer surgery. Head Neck; 2008 Aug;30(8):1124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clavicular osteomyelitis: a rare complication of head and neck cancer surgery.
  • BACKGROUND: We report the 10th case in the English-language literature describing clavicular osteomyelitis that presented after radical treatment for laryngeal carcinoma and discuss the pertinent diagnostic and therapeutic measures.
  • The differential diagnosis included tumor recurrence, metastatic bone disease, and postradiotherapy complications.
  • METHODS AND RESULTS: A 45-year-old man who was a heavy smoker and known drug abuser presented with acute airway compromise and was diagnosed with squamous cell carcinoma involving the glottis and subglottis.
  • On follow-up 1 year later, the patient was seen with left stomal dehiscence and a large area of cellulitis extending across the left clavicle and down to the axilla.
  • Biopsy showed no evidence of tumor.
  • After aggressive treatment, the patient remains disease free.
  • Aggressive surgical debridement and antibiotic therapy remains the mainstay of treatment.
  • Prompt diagnosis and treatment are mandatory due to the potential life-threatening complications associated with the condition.
  • [MeSH-major] Clavicle / microbiology. Escherichia coli Infections / diagnosis. Osteomyelitis / etiology. Postoperative Complications
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Humans. Laryngeal Neoplasms / therapy. Laryngectomy. Male. Middle Aged. Neck Dissection. Radiotherapy, Adjuvant. Staphylococcal Infections / diagnosis. Surgical Stomas. Surgical Wound Dehiscence / microbiology. Surgical Wound Dehiscence / surgery. Thyroidectomy






Advertisement